Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/2020  
 
1 
 Abbreviated Title:  Topotecan  + M6620 in Sm C ell 
CC Protocol #:  15-C-0150 M 
Version Date : 06/12/[ADDRESS_401462] Number :  [STUDY_ID_REMOVED] 
A Phase I/II T rial of T opotecan with VX-970 (M6620) , an ATR K inase I nhibitor in Small 
Cell C ancers  
 
 Investig ational Agent :     
Drug Name:  [CONTACT_94273]-970 (M6620) 
IND Number : 126291 
Sponsor: Center for Cancer Research, National Cancer Institute 
Manufacturer:  EMD Serono 
Commercial Agent : topotecan  NCI Principal I nvestigator: Anish Thomas, MBBS, M.D.  
Developmental Therapeutics Br anch  (DTB)  
Center for Cancer Research  
National Cancer Institute [ADDRESS_401463], Room 4-5330 Bethesda, MD [ZIP_CODE] Phone: [PHONE_3302] 
E-mail: anish. thomas@n ih.gov   
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/2020  
 
2 
 PRÉCIS  
Background:  
• Small cell lung c ancer (S CLC) is  an aggressiv e cancer with a poor prognosis. 
• Although highly responsi ve to ch emotherapy initially, SCLC relap ses quickly and 
becomes refractory to treatment within a few months.  
• There is o nly one FDA approved treatment for patients wit h relapsed SCL C after  first-
line c hemotherapy: topotecan, which inhi bits religation of top oisomerase I -mediated 
single- strand DNA breaks leading to lethal double- strand DNA breaks .  
• The inability to destroy re sidual SCLC cells despi[INVESTIGATOR_325171] t he 
existence of a hi ghly effect ive DNA damage response network. 
• SCLC is characterize d by [CONTACT_325184] (RB1 inactivation, MYC and CCNE1 
activation) and defe ctive ATM -p53 signaling pathw ay, which cause an excessive reliance 
on ATR for surv ival following DNA damage. 
• We hypothesize that a combination of ATR kinase inhibitio n with DNA damaging agents 
will provide an attractive synthetically lethal therapeutic option for SCLC.  
• VX-970 (M6620) is a potent and selective kinase inhibitor of A TR, an d in vitro data 
support the hypothesis that ATR inhibition can improve SCLC response s to DNA 
damaging agents. 
Primary objectives:  
• Phase I : To identify the maximum tolerated dose (MTD) of topotecan in combination 
with VX-970 (M6620). 
• Phase II : To a ssess the  efficacy with respect to clinical response rate of a combinat ion of 
topotecan and VX-970 (M6620) in previously treated pati ents with SCLC  and extra-
pulmonary small cell carcinomas . 
Eligibility:  
• Both Pha se I and II : Subject s must be ≥ [ADDRESS_401464] a performance s tatus 
(ECOG) ≤ 2. Subject s must not have received chemotherapy, or underg one major surgery 
within 2 weeks  and radiotherapy within 24 hours prior to enrollment.  
• Phase I : Subject s with histologically confirmed SCLC, NSCLC, ovarian c ancer,  cervical 
cancer, a nd neuroendocrine cancers , and a t least one prior chemotherapy . Patients with 
other histologies will be a llowed if no standard treatment options exist.  Patients with 
evaluable, but not measurable disease will be eligible  for Phase  I. 
• Phase II : Subject s with histological confirmation of SCLC and extra- pulmonary small 
cell c arcinomas. Patients with both platin um-sensitive and platinum- refractory disease 
will be eligible.   Patients must h ave measurable disease to be eligible for Phase II. 
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/2020  
 
3 
 Design:  
• Particip ants meeting inclusion and exclusion criteria will receive topotecan and VX-970 
(M6620) administered every 21  days (1 cycle), until disease progression or development 
of intolerable side e ffects.   
• Blood and hair samples will be collec ted at  multiple time points during cycle 1 (pre-
treatment  on day  1, post treatment on days 2, and 3) for PD analyses.  
• Blood for pharmacokinetic analysis , which is optional, may  be collected before and after 
topotecan and VX -970 (M6620) on days [ADDRESS_401465] to 
scheduling. 
• Tumor biopsies, which are optional, wi ll be obtained at baseline, during the f irst 
treatment cycle (approximately [ADDRESS_401466] dose of VX- 970 (M6620) on day 
3) and a t disease progression excep t for subjects at the  first dose level.  
• PBMCs will be collected cycle 1 days 1 and 2 (pre -treatme nt), post- treatment on cycle 1 
day 5 (optional) and cycle 2 day 1 (pre- treatment).  
• Participants  at the first d ose level will undergo biopsies on day [ADDRESS_401467] dose of 
topotecan. 
• Participants  will be monitored weekly during the first cycle by [CONTACT_325185]. 
• Toxicity will be graded according to CTCAE version 4.0, and t umor assessments will be 
made using CT scans (chest, abdomen and pelvis) a t baseline and after every [ADDRESS_401468] version 1.1.  
• Follow-up for survival w ill be carried out every 3 months.  
VX970+ topotecan -Phase I/II trial schema 
0 1 2 3 4 5 Days
Topotecan
VX970Biopsy
Dose level Topotecan -mg/m2 IV
(days 1 -5)VX970 -mg/m2 IV
1 1 140 on day 5
2 1 140  on days 2,5
3 1.25 140 on days 2,5
4 1.25 210on days 2,5
21 day cyclesPD
 
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/2020  
 
4 
 TABLE OF CONTENTS  
PRÉCIS  ........................................................................................................................................... 2  
TABLE OF CONTENTS  ................................................................................................................ 4  
1 INTRODUCTION  .................................................................................................................. 9  
1.1 Study Objectives .............................................................................................................. 9  
1.1.1  Primary Objective s.................................................................................................... 9  
1.1.2  Secondary Objectives ................................................................................................ 9  
1.1.3  Exploratory Objectives ............................................................................................. 9  
1.2 Background and Rationale ............................................................................................... 9  
1.2.1  Hypothesis............................................................................................................... 11  
1.2.2  VX-970 (M6620) .................................................................................................... 12  
1.2.3  Topotecan  ................................................................................................................ 16  
1.2.4  Rationale  ................................................................................................................. 16  
1.2.5  Topotecan plus VX- 970 (M6620) Phase I summary  .............................................. 16  
2 ELIGIBILITY ASSESSME NT AND ENROLLMENT  ....................................................... 17  
2.1 Eligibility Cr iteria  .......................................................................................................... 17  
2.1.1  Inclusion Criteria  .................................................................................................... 17  
2.1.2  Exclusion Criteria  ................................................................................................... 18  
2.1.3  Recruitment Strategies  ............................................................................................ 19  
2.2 Screening Evaluation ...................................................................................................... 19  
2.3 Participant Registration  and Status Update Procedures  ................................................. 20  
2.4 Treatment Assignment Procedures ................................................................................. 20  
3 STUDY IMPLEMENTATION  ............................................................................................ 20  
3.1 Study Design .................................................................................................................. 20  
3.1.1  Phase I: Dose Limiting Toxicity  ............................................................................. 21  
3.1.2  Phase I: Dose Escalation  ......................................................................................... 22  
3.1.3  Phase II .................................................................................................................... 23  
3.2 Drug Administration  ...................................................................................................... 23  
3.2.1  VX-970 (M6620) Administration ........................................................................... 24  
3.2.2  Topotecan Administration  ...................................................................................... 24  
3.3 Dose Modifications ........................................................................................................ 24  
3.3.1  VX-970 (M6620) dose modification ...................................................................... 24  
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/2020  
 
5 
 3.3.2  Topotecan dose modification .................................................................................. 25  
3.4 Study Calendar ............................................................................................................... 27  
3.5 Criteria for Removal from Protocol Therapy and Off Study Criteria ............................ 28  
3.5.1  Criteria for removal from protocol therapy ............................................................ 28  
3.5.2  Off-Study Criteria  ................................................................................................... 28  
4 CONCOMITANT MEDICATIONS/MEASURES  .............................................................. 29  
5 BIOSPECIMEN COLLECTI ON .......................................................................................... 29  
5.1 Correlative Studies for Research/Pharmacokinetic St udies ........................................... 29  
5.1.1  γ-H2AX Detection in Tumor Biopsies, hair follicles and PBMC .......................... 30  
5.1.2  Sample Collection  ................................................................................................... 31  
5.1.3  Genomic analysis  .................................................................................................... 32  
5.1.4  Circulating Nucleic Acids  ....................................................................................... 33  
5.1.5  Circulating Tumor Cells  ......................................................................................... 33  
5.1.6  Immune Subsets ...................................................................................................... 33  
5.1.7  Pharmacokinetic Studies  ......................................................................................... 33  
5.2 Sample Stora ge, Tracking and Disposition .................................................................... 34  
5.2.1  Laboratory of Jane Trepel ....................................................................................... 35  
5.2.2  Blood Processing Core (Laboratory of [CONTACT_195168]) ..................................... 35  
5.2.3  Future Use/IRB Reporting/Protocol Completion/Sample Destruction ................... 36  
5.3 Samples for Genetic/Genomic Analysis  ........................................................................ 37  
5.3.1  Description of the scope of genetic/genomic analysis ............................................ 37  
5.3.2  Description of how privacy and confidentiality of medical information/biol ogical  
specimens will be maximized  ............................................................................................... 37  
5.3.3  Certificate of Confidentiality  .................................................................................. 37  
5.3.4  Management of Results ........................................................................................... 37  
6 DATA COLLECTION AND EVALUATION  ..................................................................... 38  
6.1 Data Collection  ............................................................................................................... 38  
6.1.1  Genomic Data Sharing Plan  .................................................................................... 38  
6.2 Response Criteria  ........................................................................................................... 38  
6.2.1  Definitions ............................................................................................................... 39  
6.2.2  Disease Parameters  ................................................................................................. 39  
6.2.3  Methods for Evaluation of Measurable Disease  ..................................................... 40  
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/2020  
 
6 
 6.2.4  Response Criteria  .................................................................................................... 42  
6.2.5  Duration of Response .............................................................................................. 44  
6.2.6  Progression-Free Survival ....................................................................................... 44  
6.2.7  Response Review  .................................................................................................... 44  
6.3 Toxicity Criteria  ............................................................................................................. 44  
7 NIH REPORTING REQUIREMENTS / DATA AND SAFETY MONITORING PLAN  .. 45  
7.1 Definitions ...................................................................................................................... 45  
7.2 OHSRP Office of Compliance and Training / IRB Reporting ....................................... 45  
7.2.1  Expedited Reporting ............................................................................................... 45  
7.2.2  IRB Requirements for PI [INVESTIGATOR_10021] ................................... 45  
7.3 NCI Clinical Director Reporting  .................................................................................... 45  
7.4 NIH Required Data and Safety Monitoring Plan ........................................................... 45  
7.4.1  Principal Investigator/Research Team  .................................................................... 45  
8 SPONSOR SAFETY REPOR TING  ..................................................................................... 46  
8.1 Definitions  ...................................................................................................................... 46  
8.1.1  Adverse Event  ......................................................................................................... 46  
8.1.2  Serious Adverse Event (SA E) ................................................................................. [ADDRESS_401469]  ................................................................................ 47  
8.2 Assessment of Safety Events .......................................................................................... 47  
8.3 Reporting of Serious Adverse Events ............................................................................ 47  
8.4 Safety Reporting Criteria to the Pharmaceutical Collaborators  ..................................... 48  
8.4.1  EMD -Serono ........................................................................................................... 48  
8.5 Reporting Pr egnancy  ...................................................................................................... 49  
8.5.1  Maternal  exposure  ................................................................................................. 49  
8.5.2  Paternal exposure .................................................................................................... 49  
8.6 Regulatory Reporting for Studies Conducted Under CCR-Sponsored IND .................. 49  
9 CLINICAL MONITORING ................................................................................................. 49  
10 STATISTICAL CONSIDERATIONS .................................................................................. 50  
10.1  Determination of Sample Size ........................................................................................ 51  
11 COLLABORATIVE AGREEM ENTS  ................................................................................. 51  
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/2020  
 
7 
 11.1  Cooperative Research and Development Agreement (CRADA)  ................................... [ADDRESS_401470] Selection  ..................................................................................... 51  
12.2  Participation o f Children  ................................................................................................ 51  
12.3  Participation of Subjects Unable to Give Consent ......................................................... 51  
12.4  Evaluation of Benefits and Risks/Discomforts .............................................................. 52  
12.4.1  Risks ........................................................................................................................ 52  
12.4.2  Benefits  ................................................................................................................... 54  
12.5  Risks/Benefits Analysis for Subjects Able and Unable To Provide Consent ................ 54  
12.6  Consent Process and Documentation ............................................................................. 55  
13 PHARMACEUTICAL INFOR MATION  ............................................................................. 55  
13.1  VX-970 (M6620)............................................................................................................ 55  
13.1.1  Source ..................................................................................................................... 55  
13.1.2  VX-970 (M6620) (NSC 780162) Other Names...................................................... 56  
13.1.3  Classification ........................................................................................................... 56  
13.1.4  Molecular Formula: C2 4H26ClN5O3S M.W.: 500.01 Da ..................................... 56  
13.1.5  Mode of Action ....................................................................................................... 56  
13.1.6  Description  .............................................................................................................. 57  
13.1.7  How Supplied.......................................................................................................... 57  
13.1.8  Preparation  .............................................................................................................. 57  
13.1.9  Storage .................................................................................................................... 57  
13.1.10  Stability  ................................................................................................................... 57  
13.1.11  Route of Administration  ......................................................................................... 57  
13.1.12  Method of  Administration ....................................................................................... 57  
13.1.13  Patient Care Implications  ........................................................................................ 58  
13.1.14  Potential Drug Interactions ..................................................................................... 58  
13.1.15  Incompatibilities  ..................................................................................................... 58  
13.2  Topotecan  ....................................................................................................................... 58  
13.2.1  Administration Procedures...................................................................................... 58  
14 REFERENCES  ..................................................................................................................... 59  
15 APPENDICES  ...................................................................................................................... 60  
15.1  Appendix A- PERFORMANCE STATUS CRITERIA  ................................................. 60  
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/2020  
 
8 
 15.2  Appendix B- STRONG INHIBITORS AND INDUCERS OF CYP3A ........................ 61  
 
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/2020  
 
9 
  
1 INTRODUCTION 
1.1 STUDY OBJECTIVES  
1.1.1 Primary Objectiv es 
• Phase I : To i denti fy the maximum to lerated dose (MTD) o f topotecan in combination 
with VX-970 (M6620). 
• Phase II : To a ssess the efficacy with respect to clinical response rate of a combination of 
topotecan and VX -970 (M6620) in previously tr eated  patient s with SCLC  and extra-
pulmonary small cell carcinomas.  
1.1.2 Secondary Objectives  
• To deter mine the progression- free survival (PFS ) and overall survival (OS) of a 
combination of topotecan and VX-970 (M6620) in SCLC.  
• To assess safety and tolerabilit y of a combination of topotecan and VX-970 (M6620). 
• To identify pharmacodynamic markers of respons e. 
• To assess dura tion of response to th e combination in both platinum sensitive and 
refractory patients.  
1.1.3 Exploratory Objectives 
• To characterize gene expressi on and mutations which predict response and changes 
associated with dev elopment of chemoresistance.  
• To characterize c irculating tumor ce lls (CTC) and circulating DNA bearing tumor-
specific mutations .   
• To characterize the immunomodulatory effects of DNA damage-inducing cytotoxic 
therapy . 
1.2 BACKGROUND AND RATIONALE  
Smal l cell lung cancer (SCLC) is an aggressive cancer wi th a poor prognosis. A nnually there are 
approximately 34,000 new cases of SCLC in the [LOCATION_002]. SCLC is characterized by [CONTACT_148377], high growth fraction and early and widespread metastatic involvement. Approximately two thirds of patients pr esent with extensive -stage disease with tumor 
involvement of contralateral lung, liver, adrenal glands, brain, bones and/or bone marrow.  
The primary treatment modality for patients with exten sive- stage S CLC (ES -SCLC) is systemic 
chemother apy consisting of platinum and etoposide followed by [CONTACT_148378] a response [ 1
]. Although highly responsive to chemothe rapy initially, S CLC 
relapses quickly and becomes refractory to treatment within a few months. The median survival 
for patients with ES -SCLC ranges from 8 to 13 months. Less than 5% of patients survive two 
years and less than 2% are alive five years after diagnosis. There is only one FDA approv ed 
treatment for patients with relapsed SCLC after first-line chemotherapy: topotecan, which inhibits religation of top oisomerase I -mediated single -strand DNA breaks lead ing to letha l 
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/[ADDRESS_401471] is depi[INVESTIGATOR_6517] 1[ 2
]. Api[INVESTIGATOR_148324] -
telangiectasia mutated (ATM) and ataxia telangiectasia and Rad3 -related (ATR) are recruited via 
DNA dama ge sensors. In addition to single-stranded DNA breaks, ATR responds to genotoxic 
stress that is ca used by [CONTACT_325186], caused by [CONTACT_148380]. Eventually via 
phosporylation of a number of mediators, DNA damage response signaling converges on downst ream effector s such as p53 and the cell division cy cle 25 (CDC2 5) phosphatases.  
Figure 1. DNA damage response pa thway  
 
Despi[INVESTIGATOR_148325], defects in this pathw ay are common  in cancer. For examp le, loss of ATM signaling capacity is  
frequently observed, either through loss of expression of ATM itself, or through defects in 
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/2020  
 
11 
 upstream regulators and downstream effectors such as p53. Although they appear to confer a 
growth advanta ge, defects in ATM si gnaling cause an excessive reliance o n remaining DNA 
damage resp onse components, such as ATR, and thus provide an ‘Achilles’ heel’ that could be 
targeted by [CONTACT_8422].  
Most frequently mutated genes in SCLC are shown in Figure 2 [ 3]. SCLC is remarkable for the 
high frequency of alterations in the ATM pathway. SCLC is characterized by [CONTACT_325187] p53, a key downstream effector  of the ATM pathway. Furthermore, SCLC is also 
characterized by [CONTACT_325188]. This 
combination of high replication stress and defective ATM-p53 signaling pathway may provide a strong reliance on ATR f or survival followin g DNA damage in SCLC. 
Consequently, the combination of an inhibitor of ATR kinase with DNA damaging agents could be an attractive synthetic lethal therapeutic option for SCLC. 
Figure 2. Most frequently mutated genes in SCLC  
 
Durab le clinical response from synthetic lethal interactions between the two DNA damage 
response pathways was recently reported in a patient with small cell cancer of the urothelial tract 
[4]. The patient with  metastatic disease was treated with a combination of irinotecan and an 
experimental CHK1 inhibitor resulting in a complete response which was ongoing at three years at the time of the report.  Functional studies revealed somatic mutations that impaired Mre 11 
function, which likely resulted in synthetically lethal activity of the combination of CHK1 inhibitor with a DNA damaging agent.  
1.2.1 Hypothes is 
The inability to destroy residual SCLC cells des pi[INVESTIGATOR_325172] -sensitivity to DNA damaging 
agents suggests t he existence of a highly effective DNA damage response. SCLC is characterized 
by [CONTACT_325184] (RB1 inactivation, MYC and CCNE1 act ivation) and defective ATM -
p53 signaling pathway. S CLC therefor e relies  strongly on ATR for survival following DNA 
damage. We hypothesize that a combination of ATR kinase inhibition with DNA damaging agents will provide an attractive synthetically lethal therapeutic op tion for SCLC.  
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/2020  
 
12 
 1.2.2 VX-970 (M6620) 
VX-970 (M6620) is a n adenos ine triphosphate (ATP)- comp etitive, highly potent, tightly binding 
inhibitor of ATR with an inhibition constant (Ki) <300 pM (range <0.1 to 0.3 nM) that blocks 
ATR activity in cells, with a concentr ation associated with  50% inhibition (IC50) of 20 nM [ 5]. 
VX-970 (M6620) is very selective in inhibiting ATR; it showed >100- fold selectivity against th e 
closely rel ated DDR proteins, ATM (Ki 38 ± 30 nM [mean ± SD])  and DNA-dependent protein 
kinase ( Ki >4000 nM). ATR and ATM have overlappi[INVESTIGATOR_325173]. Accordingly, cells with defects in ATM signaling, for example from loss of p53, have been shown to be e speciall y sensitive to ATR inhibition by [CONTACT_94273]-
970 (M6620) . Minimal inhibitor y activity was observed against a large panel of unrelated protein 
kinases, with 278 of 291 kinases tested having a measured IC50 of >400 nM and a measured Ki >200 nM, corresponding to >500-fold selectivity for ATR. For 12 of the remaining 13 kinases, the Ki was >15 nM (>50- fold selectivity fo r ATR) and ≥8 nM for one of the 13 kinases, Flt4 
kinase (>25 -fold selectivity fo r ATR).  
[IP_ADDRESS]  Pre-Clinical Toxicology and Compound Safety  
Good laboratory practices (GLP) toxicology studies have been performed with both oral and intravenous formulations of VX-970 (M6620). VX -970 (M6620) administered orally to dogs for 
28 days at doses of 30, 60, and 90 mg/kg/day, given every other day, resulted in cachexia and overall deterioration of animals requiring early termination at all doses; however, all findings showed evidence of reversibility after termination of dosing. Pathologic findings included periportal vacuolation, bile duct hyperplasia, and cholestasis in the liver and testicular degeneration, as well as effects on peripheral blood cell populations. Oral administration of VX-970 (M6620) to rats for 28 days at doses of 50, 150, and 300 mg/kg/day, every other day, resulted in mortality in [ADDRESS_401472] dose only with decreases in red blood cell mass and testicular atrophy. The animal -to-human exposure multiple calculated on a weekly area 
under the concentration versus time curve (AUC) basis at the MTD (150 mg/kg/day) was 107-fold to the weekly projected human exposure at the estimated efficacious dose [ 6
].  
VX-970 (M6620) was administered to dogs intravenously for 28 days at dosages of 7.5, 15, and 20 mg/kg/day on a twice a week schedule. No mortality or adverse clinical findings were observed; decreases in hematocrit, and increases in reticulocytes, and transient elevations in alanine aminotransferase (ALT) w ere noted at the 20 mg/kg/day dose, but there were no 
correlative findings on pathologic examination. The highest non-severely toxic dose (HNSTD) was determined to be 20 mg/kg/day. The animal- to-human exposure coverage for safety was 
calculated based upon weekly AUC parameter estimates at the HNSTD (19 -fold the weekly 
projected human exposure at the efficacious dose). VX-970 (M6620) was administered 
intravenously twice weekly to rats for 28 days at doses of 5, 10, and 30 mg/kg/day. At the highest dose, anim als had mild increases in reticulocytes and platelets, and there was mortality in 
4 of 48 animals. Animals at the 10- and 30-mg/kg/day dose exhibited chronic phlebitis and anim als at all doses exhibited extramedullary hematopoiesis in the spleen. The severely toxic 
dose in 10% of animals (STD
10) was considered to be 30 mg/kg/day. The animal- to-human 
exposure multiple calculated on a weekly AUC basis at the STD 10 was 13 -fold to t he weekly 
projected human exposure at the estimated efficacious dose [ 6].  
[IP_ADDRESS]  Clinical Studies  
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/2020  
 
13 
 At this time, the following studies of VX970 are ongoing: 1) VX12 970 001 (Study 001), Phase 
[ADDRESS_401473] in human 2) VX13 970 002 (Study 002) Phase 1 3) 9771 16-C-0087 NCI 160087 Study Registry ID: [REMOVED] Phase I Study of Veliparib (ABT-888), an Oral PARP Inhibitor, and VX 970, an ATR Inhibitor, in Combination With Cisplatin in Patients With Refractory Solid Tumors 4) 9938 NCI-2015-[ZIP_CODE] UPCI 15- 164 ClinicalTrials. gov Identifier: 
[STUDY_ID_REMOVED] Phase I Clinical Trial of VX-970 in Combination With the Topoisomerase I Inhibitor Irinotecan in Patients With Advanced Solid Tumors 5) DF/HCC Protocol 16 322 NCI Protocol 9944 Study Registry ID: [REMOVED] Phase 2 Study of VX 970 (NSC# 780162) in Combination with Gemcitabine versus Gemcitabine Alone in Subjects with Platinum-Resistant Recurrent Ovarian or Primary Peritoneal Fallopi[INVESTIGATOR_325174] 6) PhII 135 NCI Protocol 9947 Study Registry ID: [REMOVED] Phase 2 A Randomized Phase 2 Trial of Cisplatin/Gemcitabine with or without VX 970 in Metastatic Urothelial Carcinoma.  
[IP_ADDRESS]  Clinical Safety  
Single-agent Therapy  
VX-970 (M6620) was administered as a single agent in the lead -in periods of Study 001 Parts A 
and B (doses of 18 mg/m2 to 210 mg/m2, lead -in periods of 7 to 21 days); during 
Study 002 Part  A1 (once weekly, doses of 60 mg/m2 to 480 mg/m2) and Part  A1 (twice weekly, 
doses of 240 mg/m2); and during the single-agent phase of Study 002 Part C (doses of 
240 mg/m2). 
VX-970 (M6620) was generally well tolerated as a single agent. There were no dose- limiting 
toxicities (DLTs), few adverse events (AEs) leading to study drug discontinuation, and [ADDRESS_401474] subjects receiving single- agent VX-970 (M6620) had AEs. The System 
Organ Classes (SOCs) in which AEs occurred most frequently were Gastrointestinal Disorders and General Disorders and Administration Site Conditions. The most commonly occurring AE was nausea.  
The SOCs in which serious adverse events (SAEs) occurred most frequently were Neoplasms Benign, Malignant, and Unspecified; Respi[INVESTIGATOR_696], Thoracic, and Mediastinal Disorders; and Gastrointestinal Disorders. SAEs tha t occurred in more than [ADDRESS_401475] receiving single- agent 
VX-970 (M6620) were met astases to central nervous system, malignant neoplasm progression, 
dyspnea, nausea, and blood creatinine increased. Most of the SAEs were assessed as not related to study drug. 
Combination Therapy 
VX-970 (M6620) + Gemcitabine 
In Study 001 Part A1, 49 of 50 subjects (98.0%) had at least 1 AE. AEs of nausea, fatigue, 
alanine transaminase (ALT) increased, and anemia occurred in more than 50% of subjects . 
Twenty -four subjects (48.0%) had at least [ADDRESS_401476] 
were pyrexia (6  subjects, 12.0%) and cellulitis, dehydration, musculoskeletal pain, 
thrombocytopenia, and vomiting (each in 2 subjects, 4.0%). Thirty-eight subjects (76.0%) had at 
least 1 Grade ≥3  AE. Grade  ≥[ADDRESS_401477] 10% of subjects were neutropenia, 
anemia, thrombocytopenia, ALT increased, and fatigue. DLTs occurred in 4 of 45 subjects (8.9%) in the DLT Evaluable Set and included ALT increased and aspartate transaminase (AST) increased, each in 2  subjects (4.4%) and blood alkaline phosphatase increased, 
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/[ADDRESS_401478] (2.2%). Nine subjects (18.0%) had AEs leading 
to study drug discontinuation. One subject (2.0%) had a fatal SAE of disease progression of NCSLC that was unrelated to either study drug. 
In Study 001 Part  C1, 31 of 33 subjects (93.9%) had at least [ADDRESS_401479] common AEs were 
anemia (15  subjects, 45.5%) and fatigue (14 subjects, 42.4%). Seventeen subjects (51.5%) had at 
least [ADDRESS_401480] were vomiting, fatigue, pneumonia, 
sepsis, and dyspnea (each in 2 subjects, 6.1%). Nineteen subjects (57.6%) had at least 
1 Grade ≥3 AE. Grade  ≥[ADDRESS_401481] 10% of subjects were f atigue and 
neutropenia. Two subjects (6.1%) had AEs leading to study drug discontinuation, which included vomiting and fatigue, each in [ADDRESS_401482] (3.0%) had an AE leading to death (coded as abdominal pain). 
VX-970 (M6620) + Cisplatin  
In Study 001 Part B, 29 of 30 subjects (96.7%) had at least [ADDRESS_401483] common AE was 
nausea (15  subjects, 50.0%) . Eleven  subjects (36.7%) had at least [ADDRESS_401484] were infusion- related reaction, ALT increased, and AS T 
increased (each in 2  subjects, 6.7%). Twenty -one subjects (70.0%) had at least 1 Grade ≥3 AE. 
Grade ≥[ADDRESS_401485] 10% of subjects were neutropenia and anemia. DLTs 
occurred in 2 of 29 subjects (6.9%) in the DLT Evaluable Set and included ALT increased and flushing, each in [ADDRESS_401486]. Six  subjects (20.0%) had AEs leading to study drug discontinuation. 
There were no AEs leading to death.  
In Study 001 Part C2, 34 of 35 subjects (97.1%) had at least 1 AE. AEs of nausea and fatigue 
occurred  in more than 50% of subjects . Seven  subjects (20.0%) had at least [ADDRESS_401487] were vomiting (3 subjects, 8.6%) and nausea and pyrexia 
(each in 2  subjects, 5.7%). Eighteen subjects (51.4%) had at least 1 Grade ≥3 AE . Grade ≥[ADDRESS_401488] 10% of subjects were neutropenia, anemia, and vomiting. Eight subjects (22.9%) had AEs leading to study drug discontinuation. There were no AEs leading to death.  
In Study 001 Part C3, 2 subjects received VX -970 (M6620) in combination with cisplatin. 
Both subjects had at least [ADDRESS_401489] (50.0%) had 3 Grade ≥[ADDRESS_401490] had 
an AE leading to study drug discontinuation or to death. VX-970 (M6620) + Carboplatin In Study 002 Part B1, all 23 subjects (100%) had at least 1 AE. AEs of n ausea and anemia 
occurred in more than 50% of subjects. Eight subjects (34.8%) had at least [ADDRESS_401491] was pyrexia (3  subjects, 13.0%). Eleven  subjects (47.8%) 
had at least 1  Grade ≥3  AE. Neutropenia was the only Grade ≥3  AE that occurred in at leas t 10% 
of subjects. DLTs occurred in 3 of 23 subjects (13.0%) in the DLT Evaluable Set and included febrile neutropenia, neutropenia, thrombocytopenia, hypersensitivity, and lower res pi[INVESTIGATOR_4348]. Four subjects (17.4%) had AEs leading to study drug discontinuation. There were no AEs leading to death. 
In Study 001 Part C3, 8 subjects (80.0%) had at least [ADDRESS_401492] common AEs were 
thrombocytopenia and fatigue (each i n 4 subjects, 40.0%) . Two  subjects (20.0%) had at least 
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/2020  
 
15 
 1 SAE; SAEs were superior vena cava syndrome and failure to thrive. Six subjects (60.0%) had 
at least 1  Grade ≥3  AE. The Grade ≥[ADDRESS_401493] (10.0%) had 
an AE leading to study drug discontinuation. There were no AEs leading to death. 
In Study 002 Part C, all 11  subjects (100.0%) in the Combination Safety  Set had at least [ADDRESS_401494] common AE was anemia (5  subjects, 45.5%). Five  subjects (45.5)% had at least 
[ADDRESS_401495] was thrombocytopenia (2 subjects, 
18.2%). Seven subjects (63.6%) had at least 1 Grade  ≥3 AE. Grade  ≥[ADDRESS_401496] were thrombocytopenia (3 subjects, 27.3%) and neutropenia and anemia (each in 2 subjects, 18.2%). Four subjects (36.4%) had AEs leading to study drug discontinuation, and [ADDRESS_401497]  (9.1%) had a fatal AE of bronchitis. 
VX-970 (M6620) + Gemcitabine + Cisplatin  
In Study [ADDRESS_401498] 1  AE. AEs that 
occurred in more than 50% of subjects were fatigue, nausea, and neutropenia. Five subjects (62.5%) had at least [ADDRESS_401499]. All 8  subjects 
(100.0%) had at least 1 Grade ≥3  AE. The only Grade ≥[ADDRESS_401500] were neutropenia (5  subjects, 62.5%) and thrombocytopenia (3 subjects, 37.5%). Three 
subjects (37.5%) had DLTs, including neutropenia, febrile neutropenia, and thrombocytopenia. One subject had AEs leading to study drug discontinuation. No subject had a fatal AE. 
VX-970 (M6620) + Carboplatin + Paclitaxel In Study 002 Part B2, 8 of 9  subjects (88.9%) had at least 1 AE. AEs that occurred in more than 
50% of subjects were neutropenia and fatigue. Two subjects (22.2%) had at least 1 SAE; SAEs 
were febrile neutropenia and thrombocytopenia. Seven subjects (77.8%) had at l east 
1 Grade ≥3  AE. Grade ≥[ADDRESS_401501] were neutropenia (6  subjects, 
66.7%), anemia (3 subjects, 33.3%), and thrombocytopenia (2 subjects, 22.2%). One subject (11.1%) had a DLT of thrombocytopenia. Two subjects (22.2%) had AEs leading to study drug discontinuation, including neutropenia, thrombocytopenia, and drug hypersensitivity. No subject had a fatal AE.  
[IP_ADDRESS]  Adverse Drug Reactions  
After careful assessment, infusion -related reactions, nausea, and vomiting are considered adverse 
drug reactions (ADRs) for VX-970 (M6620), and myelosuppression events are considered ADRs for VX- 970 (M6620)  in combination with carboplatin. 
Infusion- related reactions are common with IV administration of drugs used to treat cancer. 
These reactions occur  during or shortly after administration of the drug, may be local and/or 
systemic, and are diverse.  
Systemic infusion -related reactions to VX -970 (M6620) may include signs or symptoms such as 
pruritus, flushing, chills/rigors, urticaria/rash, headache, bronchospasm/dyspnea, and hypotension or hypertension, among others. Some systemic infusion- related reactions to VX -970 
(M6620) have been serious, including those described as acute hypersensitivity reactions. Local infusion- related reactions to VX-970 (M6620), sometimes described as infusion site reactions, 
may include signs or symptoms such as infusion site erythema, swelling, or pain. 
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/[ADDRESS_401502] occurred commonly in patients receiving VX-970 (M6620) 
monotherapy. Many of the affected subjects experienced these events on the same day as VX -
970 (M6620) was administered, and there was some suggestion of a dose response. 
Myelosuppression AEs for subjects who received VX-970 (M6620) in combination with 
carboplatin have included neutropenia, thrombocytopenia, platelet count decreased, and febrile 
neutropenia. 
1.2.[ADDRESS_401503] -line chemotherapy, and as a combination therapy with cisplatin for Stage IV-B, 
recurrent, or persistent carcinoma of the cervix which is not amenable to curative treatment with surgery and/or radiation therapy. Topotecan is a semi- synthetic derivative of camptothecin  and is 
an anti -tumor drug with topoisomerase I- inhibitory activity.  Topotecan binds to the 
topoisomerase I -DNA complex and prevents religation of these single-strand breaks. The 
cytotoxicity of topotecan is thought to be due to double-strand DNA damage produced during DNA synthesis, when replication enzymes interact with the ternary complex formed by [CONTACT_148383], topoisomerase I, and DNA. Mammalian cells cannot efficiently repair these double strand breaks. Bone marrow suppression (primarily neutropenia) is the dose- limiting toxicity of  
topotecan.
  
1.2.4 Rationale  
VX-970 (M6620) is a potent and selective kinase inhibitor of ATR. In vitro data support the hypothesis that ATR inhibition can improve SCLC responses to DNA damaging agents. Specifically, VX- 970 (M6620)  markedly sensitized SCLC cell lines, but not normal cells, to 
multiple DNA damaging drugs. In matched NSCLC cell lines differing only in p53 status, p53 loss of function, through deletion, influenced cell sensitivity to ATR inhibition  [7, 8
]. The 
Pommier lab has shown that VX-970 (M6620) potentiates the cytotoxicity of both camptothecins and the non-camptothecin LMP -400 [
8]. In NSCLC and colon cancer models, VX-970 (M6620) 
enhanced the in vivo tumor response to a broad range of DNA damaging agents without additional toxicity.  
Although our goal is to assess the activity of the combination primarily in SCLC, we propose to include NSCLC, ne uroendocrine cancers, cervical and ovarian cancers in the phase I trial to 
expedite the determination of the MTD of the combination and to assess for any potential early signals of activity in these other tumors. Topotecan is an approved agent for previously treated cervical and ovarian cancers. Although not an approved treatment, topotecan has activity in NSCLC wher e a phase III trial has found that topotecan was not inferior to docetaxel  [9
].  
Patients with other histologies will be allowed if no standard treatment options exist.  
1.2.5 Topotecan plus VX -970 (M6620)  Phase I summary  
Between Sep tember  2016 and Feb ruary  2017, 21 patients (DL1: 6; DL2: 6; DL3: 3; DL4: 6) 
were treated. M/F: 9/12, ECOG PS 1/2: 19/2, median age: 61 years (range 27-69), primary tumor: small cell 6 (small c ell lung 5, small cell cervix 1), mesothelioma 4, non- small cell lung 
cancer, pancreatic, rectal neuroendocrine carcinoma 2 each, others 4), median prior lines of systemic therapi[INVESTIGATOR_014] 3 (range 1 -6). VX -970 (M6620) was generally well tolerated in combination 
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/2020  
 
17 
 with topotecan with mainly Gr1 -2 toxicities. One patient each at DL1, DL2 and DL4 had DLTs 
(Gr4 neutropenia > [ADDRESS_401504]/ALT; Gr4 thrombocytopenia requiring transfusion, Gr3 febrile neutropenia; Gr4 thrombocytopenia requiring transfusion). DL4 was determined to be the MTD. Gr 3/4 toxicities in ≥10% of patients included neutropenia (n=3/8), lymphopenia (n=7/2), anemia (9/0), thrombocytopenia (2/3), and leucopenia (8/2). Of 19 evaluable patients, 2 had partial responses, 8 had stable disease and 9 had progressive disease. Among 6 evaluable patients with small cell cancer, all of whom had platinum resistant or refractory disease, 1 patient had a partial response, 2 patients had prolonged stable disease (11 months and ongoing at 3 months).  In summary, VX-970 (M6620) was generally well tolerated in combination with topotecan. The MTD of the combination was VX-970 (M6620) 210 mg/m2 on days 2 and 5 with topotecan 1.25 mg/m2 on days 1-5. 
2 ELIGIBILITY ASSES SMENT AND ENROLLMENT   
2.1 E
LIGIBILITY CRITERIA  
2.1.1 Inclusion Criteria  
[IP_ADDRESS]  Both Phase I and Phase II:   
[IP_ADDRESS].1 Male and female subjects ≥ 18 years of age . Because no dosing adverse event data are 
currently available on the use of topotecan in combination with VX-970 (M6620) in  
subjects  <18 years of age, children are excluded from this study, but will be eligible 
for future pediatrics trials.  
[IP_ADDRESS].2 ECOG performance status ≤ 2 (See Appendix A )  
[IP_ADDRESS].[ADDRESS_401505] 1.1.  See Sectio n 6.2 for the 
evaluation of measurable disease.  Subjects with evaluable, but not measurable disease 
will be eligible for Phase I.  
[IP_ADDRESS].[ADDRESS_401506] received che motherapy, or undergone major surgery within 2 
weeks and radiotherapy within 24 hours prior to enrollment. 
[IP_ADDRESS].5 Adequate organ functions 
• Hemoglobin ≥ 9.0 g/dL  
• Absolute neutrophil count ≥ 1.5x109/L 
• Platelets ≥ 100x109/L 
• Total Bilirubin ≤ 2.0 mg/dL  
• Transaminases ≤ [ADDRESS_401507] or if liver metastases were present, ≤ [ADDRESS_401508]  
• Creatinine ≤ 1.5 mg/dL or creatinine clearance  by [CONTACT_325189]-Gault formula  ≥ 60 
mL/min  
[IP_ADDRESS].[ADDRESS_401509] to understand and the willingness to sign a written informed consent 
document. 
[IP_ADDRESS].7 The effects of VX -970 (M6620) on the developi[INVESTIGATOR_19241].  For this 
reason and because topotecan is known to be teratogenic, women of child-bearing 
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/[ADDRESS_401510] agree to use adequate contraception (hormonal or barrier 
method of birth control; abstinence) prior to study entry, during study participation and for [ADDRESS_401511] she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. 
[IP_ADDRESS]  Phase I :  
[IP_ADDRESS].[ADDRESS_401512].  
[IP_ADDRESS].[ADDRESS_401513] one prior chemotherapy  
[IP_ADDRESS].[ADDRESS_401514] previously 
received appropriate FDA approved therapi[INVESTIGATOR_325175] 
[IP_ADDRESS]  Phase II : 
[IP_ADDRESS].[ADDRESS_401515]. 
[IP_ADDRESS].2 Subjects  with both platinum-sensitive and platinum- refractory disease will be eligible  
2.1.2 Exclusion Criteria  
[IP_ADDRESS]  Subject s with tumor amenable to potentially curative therapy. 
[IP_ADDRESS]  Subject s who are receiving any other investigational agents.  
[IP_ADDRESS]  History of allergic reactions attributed to compounds of similar chemical or biologic composition to (study agent) or other agents used in stu dy. 
[IP_ADDRESS]
 Subject s with symptomatic brain metastases will be excluded from trial secondary 
to poor prognosis.  However, subject s who have had treatment for their brain 
metastasis and whose brain disease is stable without steroid therapy for 1 week or 
on physiologic doses of steroids may be enrolled. 
[IP_ADDRESS]  Subjec ts requiring  any medications or substances that are strong inhibitors or 
inducers of CYP3A during the course of  the study are ineligible.  Lists including 
strong inhibitors and inducers of  CYP 3A4  are provided i n Appendix B (Strong 
Inhibitors and Inducers of CYP3A) . 
[IP_ADDRESS]  Subject s with evidence of severe or uncontrolled systemic disease, or any 
concurrent condition, which could compromise participation in the study, including, but not limited to, active or uncontrolled infection, immune deficiencies, Hepatitis B, Hepatitis C, uncontrolled diabetes, uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction within the past 6 m onths, uncontrolled cardiac arrhythmia, stroke/cerebrovascular accident 
within the past 6 months, or psychiatric illness/social situations which would jeopardize compliance with the protocol .   
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/2020  
 
19 
 [IP_ADDRESS]  HIV-positive subject s on combination antiretroviral therapy ar e ineligible because 
of the potential for pharmacokinetic interactions with VX-970 (M6620) .  In 
addition, these subjects are at increased risk of lethal infections when treated with 
marrow-suppressive therapy.   
[IP_ADDRESS]  Pregnant women are excluded from this study because topotecan   is a Class D  
agent with the potential for teratogenic or abortifacient effects  and because t he 
effects of VX-970 (M6620)  on the developi[INVESTIGATOR_148339].  
In addition, because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with topotecan or VX-970 
(M6620) , breastfeeding should be discontinued if the mother is treated with these 
agent s.   
2.1.3 Recruitment Strateg ies 
This protocol may be abstracted into a plain language announcement posted on NIH websites and on NIH social media platform s.   
2.2 S
CREENING EVALUATION  
Screening evaluation  testing/procedures are conducted under the separate screening  protocol, 01-
C-0129 (Eligibility Screening and Tissue Procurement f or the NIH Intramural Research Program 
Clinical Protocols) . Assessments performed at outside facilities or on another NIH protocol 
within the timeframes below may also be used to determine eligibility once a patient has signed the consent. 
Screening must be completed within 2 weeks  (except viral m arkers s creen  that could be 
performed within 4 months) prior to enrolling subjects onto the protocol.  
1. History and physical exam (including height, weight, and vital signs) 
2. Blood tests (for organ function): 
• Complete blood count (CBC /Diff ) 
• Acute care panel  
• Hepatic panel  
• Mineral panel  
• Prothrombin time (PT)  
• Partial thromboplastin time ( PTT)  
3. Viral Markers Protocol Screen (HBsAg, anti-HCV, anti- HIV)  
4. Confirmation of diagnosis by [CONTACT_325190] (can be done prior to the 
two-week scre ening window) Note:  NCI confirmation of pathology is not required prior 
to starting treatment, but every effort should be made to obtain outside pathology to be reviewed by [CONTACT_325191]. 
5. CT scan  of disease sites  
6. Electrocardiogram (12 lead) 
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/2020  
 
20 
 7. Urine or serum HCG for women of child- bearing potential  (to be performed within 5 
days prior to C1D1) 
2.3 PARTICIPANT REGISTRATION  AND STATUS UPDATE  PROCEDURES  
Registration and status updates (e.g. when a participant is taken off protocol therapy and when a 
participant is taken off-study) will take place per CCR SOP ADCR -2, CCR Participant 
Registration & Status Updates found here  
2.[ADDRESS_401516] treatment exists  
2 Phase II ( SCLC) Patients with  measurable  SCLC.  
3 Phase II (extrapulmonary 
small cell cancer ) Patients with measurable SCLC or extrapulmonary small cell 
cancer . 
Arms  
Number  Name  [CONTACT_62578]  
1 Phase I  VX-970 (M6620)  + topotecan  at escalating doses  
2 Phase II  VX-970 (M6620)  + topotecan  at MTD/RP2D  
Arm Ass ignment  
Up to 24 subjects in cohort 1 will be directly assigned to  arm 1.  
Up to 25 subjects with Small Cell Lung Cancer and up to 15 subjects with extrapulmonary small cell cancers  in cohorts 2 and 3 respectively will be directly assigned to arm 2. 
3 STUDY I MPLEMENTATION  
3.1 S
TUDY DESIGN  
This is a Phase  I/II, open label clinical trial.  The objectives of this study are to identify the 
maximum tolerated dose (MTD) of topotecan in combination with VX-970 (M6620) in a phase I trial, and to a ssess the efficacy with respect to clinical response rate of a combination of 
topotecan and VX -970 (M6620) in the second- line treatme nt of subject s with SCL C in a phase II 
trial. Participants meeting inclusion and exclusion criteria ( Section  2.1) will r eceive topotecan 
(on days 1- 5) and VX-970 (M6620) (on day 5 or 2 and 5) administered every 21 days (1 cycle), 
either in the in -patient or out- patient setting , until disease progression or development of 
intolerable side effects.  Subject s will be monitored weekly during the first cycle by [CONTACT_325192] 
(CBC with diff erential  on days 8 and 15; chemistries- acute panel, hepatic panel, miner al panel 
and troponin on days 8 and 15).  During the first cycle, basic labs may be performed at patient’s 
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/2020  
 
21 
 local physician and faxed to the research team. For the following cycles, subjects  will be seen 
every 3 weeks.  After study treatment,  follow-up for survival will be carried out every 3 months.  
Blood and hair samples will be collected at multiple time points during cycle 1  (pre-treatment, 
day on day 1, post treatment on days 2 and 3) for PD analyses. Tumor biopsies which are 
optional will be obtained at baseline, during the first treatment cycle (approximately [ADDRESS_401517] dose of VX-970 (M6620) on day 3) and at disease progression except for subject s 
at the first dose level. Subject s at the first dose level will undergo biopsies on day [ADDRESS_401518] 
dose of topotecan.  
3.1.1 Phase I: Dose Limiting Toxicity   
Subjects will be monitored for DLTs during the first cycle. DLTs will be defined using the 
National Cancer Institute (NCI) CTCAE (Version 4). 
A DLT is defined as related or possibly drug-re lated:  
• Neutropenia Grade 4 for >7 days duration*  
• Febrile neutropenia (fever of unknown origin without clinically or microbiologically 
documented infection)  
• Infection (documented clinically or microbiologically) with Grades 3 or 4 neutropenia (absolute neutrophil count <1.0 x 10
9/L)  
• Thrombocytopenia Grade 3: 
o associated with clinically significant bleeding  
o requiring platelet transfusion  
• Thrombocytopenia Grade 4 for >7 days duration* 
• Grades 3 or 4 toxicity to organs other than the bone marrow including Grades 3 and 4 biochemical AEs and DLTs, excluding the following: 
o Grade [ADDRESS_401519] not received optimal therapy for mucositis  
• Death due to drug related adverse events  
• Cardiac:  
o QTcF prolongation (any QTcF interval ≥500 msec or any change in QTc F interval 
≥60 msec from baseline) on E CG, unless related to an electrolyte abnormality and 
prolongation resolves with correction of electrolyte abnormality 
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/2020  
 
22 
 o Any of the following (CTCAE criteria): Grade 2 or greater ventricular arrhythmia 
(second or third degree atrioventricular (AV) block), severe sustained/symptomatic sinus bradycardia less than 45 beats per minute (bpm) or sinus tachycardia >120 bpm not due to other causes (e.g., fever), persistent supraventricular arrhythmia (e.g., uncontrolled/new atrial fibrillation, flutter, atrioventricu lar nodal tachycardia, etc.) lasting more than 24 hours, ventricular 
tachycardia defined as >9 beats in a row or any length of torsades de pointes (polymorphic ventricular tachycardia with long QTcF), or unexplained recurrent syncope 
o Symptoms suggestive of congestive heart failure with confirmed Ejection Fraction (EF) <40% (by 2D-echocardiogram or Multiple Gated Acquisition [MUGA] scan) or a relative decrease >20% from historical assessment of EF performed within 12 months 
o Troponin- T: level which is consiste nt with myocardial infarction  
• Any drug related toxicity that causes interruption of treatment for >3 weeks ( 21 
successive days). If a subject is deemed fit to restart treatment on Day 21then this is not a DLT.  
*Note: In the event of a Grade [ADDRESS_401520] will be closely monitored until resolution to Grade 3 or less. 
3.1.2 Phase I: Dose Escalation  
The starting dose of VX -970 (M6620) is based on the safety information from the trial of single-
agent VX- 970 (M6620)  and preliminary data from trials combining VX-970 (M6620) with 
gemcitabine , cisplatin or carboplatin. The study will follow a 3+3 design: dose will be es calated 
in cohorts of 3 patients with the individual dose of VX-970 (M6620) and topotecan increased in 
successive dose levels as outlined in the dose escalation table below. In case there is safety 
problem with the first dose, there will be a dose de- escalation to 105 mg/m2 of VX-970 (M6620) 
(25%), as indicated in the table below. The MTD is the dose level at which no more than [ADDRESS_401521] 2 (of ≤6) subject s have DLT as a 
result of the drug. If a subject did not experience DLT and did not finish treatment, he or she will 
not be evaluable for toxicity and will be replaced in the dose l evel.  
Table 1
. Dose Escalatio n Schedule  
Dose Level  Topotecan – mg/m2 IV 
(days 1-5) VX-970 (M6620) – mg/m2 IV  
Level -1 1 105 on day 5 
Level 1  1 140 on day 5 
Level 2  1 140 on days 2,5 
Level 3  1.25 140 on days 2,5 
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/[ADDRESS_401522] s. Subjects will be treated at the 
identified MTD.  
3.2 DRUG ADMINISTRATION   
Study drug may be dispensed only under the supervision of the investigator or an authorized 
designee and only for administration to the study subjects.   The drugs will be admini stered 
sequentially , with topotecan followed 15 minutes later by [CONTACT_94273]- 970 (M6620) . Level [ADDRESS_401523] s with 
DLT  
at a Given Dose Level Escalation Decision Rule 
0 out of 3 Enter up to 3 subjects at the next dose level  
> 2 Dose escalation wil l be stopped.  This dose level will 
be declared the maximally administered dose (highest dose administered).  Up to t hree (3) 
additional subject s will be entered at the next low est 
dose level if only [ADDRESS_401524] s at this dose level.  
• If [ADDRESS_401525] s experience DLT, proceed 
to the next dose level. 
• If 1 or more of this group suffer DLT, then dose escalation is stopped, and this dose is declared the maximally administered dose.   UP to t hree (3) 
additional subjec ts will be entered at the next 
lowest dose lev el if only [ADDRESS_401526] s were treated 
previously at that dose. 
<[ADDRESS_401527] be entered at the recommended phase 2 dose. 
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/2020  
 
24 
 3.2.1 VX-970 (M6620) Administration  
VX-970 (M6620) will be supplied as 20 mg/mL VX-970 (M6620) to be diluted with 5% 
dextrose in water solution before intravenous infusion as detailed in section 13.1.12. 
An appropriate volume of concentrated drug product solution is diluted before use, according to 
the dose indic ated in Table 1. Total dose is not to exceed 800 mg of VX-970 (M6620)/dose.  
The dose of VX -970 (M6620) in dextrose in water solution will be infused intravenously over 60 
minutes  (+/- 10 minutes). 
To minimize the possibility of phlebitis , VX-970 (M6620) should be administered through a 
large bore catheter into a large caliber peripheral vein  or via central venous access . The 
intravenous infusion site should be monitored closely for the development of erythema, induration, purulence, tenderness, or warmth. 
If any subject develops phlebitis or signs or symptoms of inflammation that may progress to 
phlebitis or which the subject cannot tolerate, standard measures should be employed to ameliorate these symptoms, including removal of the infusion catheter and resumption of infusion through a different vein.  If any subject develops pruritus or evidence of allergic reaction, standard measures may be employed to ameliorate these symptoms or to prevent recurrence of these symptoms (e.g., premedicat ion with acetaminophen 325 mg PO 
approximately 30 minutes before the infusion, 200 mg hydrocortisone intravenously approximately 60 minutes before infusion, and 25 mg diphenhydramine intravenously approximately 30 minutes before infusion; alternative antihistamine and steroid combinations may be considered, as long as not prohibited by [CONTACT_990]). If standard procedures to limit symptoms of injection site reaction or pruritus are insufficient, then the infusion time may be extended beyond 60 minutes, but no more than 90 minutes.  
3.2.2 Topotecan Administration  
Topotec an is a cytotoxic antica ncer drug. Prepare topotecan under a  vertical laminar flow hood 
while wearing gloves and protective clothing. If topotecan solution contacts the skin, wash the skin immediately a nd thoroughly with soap and water. If topotecan contacts mucous membranes, 
flush thoroughly with water. Use procedures for proper handling and disposal of anticancer 
drugs.  
Each 4 -mg vial of topotecan is reconstituted with  4 mL Sterile Water for Injection . Then the 
appropriate volume of the reconstituted solution is diluted in eith er 0.9% Sodium Chloride 
Intravenous Infusion or 5% Dextrose Intravenous Infusion prior to administration.
  Topotecan 
will be administered as an intravenous infusion over 30 minut es. 
3.3 DOSE MODIFICATIONS  
3.3.1 VX-970 (M6620) dose modificatio n 
No dose modifications of VX-970 (M6620) may be made during Cycle 1. The dose of VX -970 (M6620) may be reduced other than in Cycle 1 for toxicity using the 
following guidelines depending on the toxicities (and drug deemed to be responsible for toxicity) 
observed: 
1. For Grade 4 hematologic toxicity: The dose of VX-970 (M6620) will be reduced by 25%. 
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/2020  
 
25 
 2. For Grade 3 non- hematologic toxicity  (except disease related hyponatremia for which dose 
reduction will only be made for grade 4): The dose of VX- 970 (M6620) will be reduced by 25%. 
3. For Grade 4 non-hematologic toxicity: The dose of VX- 970 (M6620)  will be reduced by 50%. 
Based on the criteria above, a maximum of 2 dose reductions will be permitted. If a grade 4 non-
hematologic toxicity  were to recur, treatm ent will be discontinued. Please see table below 
indicating VX-970 (M6620) dose reductions within each dose level.  
Dose  
Level  Dosage Schedule 
100% 75% 50% 
1 140 mg/m2 on Day 5 105 mg/m2 on Day 5 70 mg/m2 on Day 5 
2 & 3 140 mg/m2 per dose, 
Days 2 and 5 105 mg/m2 per dose, 
Days 2 and 5 70 mg/m2 per dose, 
Days 2 and 5 
4 210 mg/m2 per dose, 
Days 2 and 5 158 mg/m2 per dose, 
Days 2 and 5 105 mg/m2 per dose, 
Days 2 and 5 
- 1 105 mg/m2 on Day 5 79 mg/m2 on Day [ADDRESS_401528] a DLT for VX- 970 (M6620)  will continue on topotecan. 
3.3.2 Topotecan dose modification 
No dose modifications of topotecan may be made during cycle 1.  
The dose of topotecan may be reduced other than in Cycle 1 for toxicity using the following 
guidelines depending on the toxicities (and drug deemed to be responsible for toxicity) observed, see Table 3.  Topotecan dose reductions will be accomplished by [CONTACT_325193] 5 days. 
To initia te subsequent cycles of topotecan the day 1 ANC should be >1500/mm3 and platelets 
>100,000/mm3. Treatment interruptions may occur for a maximum of 21 days. Based on the below cri teria, a maximum of 2 dose reductions will be permitte d.  
Table 3. Dose Adjustments  
A. Dose adjustments for renal functions 
Creatinine clearance  
(Cock croft-Gault formula)  Dose adjustment ( % decrease in topotecan dose ) 
DL1 and 2 DL3 and 4 
>60 no adjustment no adjustment 
40-59 -20% -20% 
20-39 -25% -25% 
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/2020  
 
26 
 <20 Discontinue Discontinue 
 
B. Dose adjustments for non -hematologic toxicities  
Non-hematologic toxicity  Dose adjustment (% decrease in topotecan dose ) 
DL1 and 2 DL3 and 4 
Grades 1 and 2  no adjustment no adjustment 
Grades 3 an d 4 (except grade 3 naus ea) -20% -20% 
 
C. Dose adjustments for hematologic toxicities  
Hematologic toxicity  Dose adjustment (topotecan mg/m2) 
DL1 and 2 DL3 and 4 
Grades 1 and 2  no adjustment no adjustment  
Grade 3 neutropenia persisting after day 21 -20% -20% 
Grade 4 thrombocytopenia or Grade 4 neutropenia 
with fever or infection or of duration ≥ 7 days  -20% -20% 
In addition, in case of Grade [ADDRESS_401529] returne d to Grade 2 or less, at 
the discretion of the investigator.  
Subjects who develop intolerance to topotecan, but who may be benefiting from therapy, may 
continue on single agent VX-970 (M6620), administered once weekly (on days 1, 8, 15 of 21 day 
cycle) at  the same dose they have received in combination therapy, until disease progression. 
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/2020  
 
27 
 3.4 STUDY CALENDAR  
On-study assessments can be performed within ±7 days of the specified  time, u nless otherwise 
indicated.  
Next cycle treatment may be delayed up to 7 days  to accommodate scheduling conflicts.  
Procedure  
Screening  Cycles = 21 days1 
End of 
Treatment17/ 
Disease 
Progression  
Post Therapy 
Follow- up4 
Day 
[ADDRESS_401530] scan  x        x12   
Clinical disease 
assessment          x12 x  
ECG  x  x13   x13      
Correlative Studies2:            
Blood   x x x        
Hair   x x x        
Circulatin g Nucleic Acids   x9        x  
Circulating Tumor Cells   x9        x  
PBMC19  x x   x20      
PK21  x          
Biopsies10 (optional)   x  x      x  
Topotecan   x x x x x      
VX-970 (M6620)[ADDRESS_401531] s.  
2  Correlative studies a re only performed during cycles 1, 2 and at disease progression . 
3  Symptom- directed physical examinations will be performed as clinically indicated i n the investigator’s 
judgment  
4  Follow- up for surviva l will be carried out ev ery 3 months  
5  Includes  Neutrophils, Lymphs, Monos, Eos, Basos, WBC, RBC, Hemoglobin, Hematocrit, RBC 
Indices, MCV, RDW, Platelet  
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/2020  
 
28 
 6  Includes Sodium (NA), Potassium (K), Chlorid e (CL) Total CO2 (Bicarbonate), Creatinine, Glucose, 
Urea nitrogen, eGFR  
7  Includes  Alkaline Phosphatase, ALT/GPT, AST/GOT, Total Bilirubin, Direct Bilirubin 
8  Only for women of child -bearing potential 
9  Will be collected  at cycle 2 day 1 in addition to cycle 1 day 1. 
10  Will be obtained at baseline  (pre-treatment), on day [ADDRESS_401532] dose level.  
11  Taken on day 5, or day 2 and 5, as indicated in Section 3.1.2  
12  Performed after every 2 cycles 
13 ECG will be performe d predose ( within the 120 minutes before the start of VX-970 (M6620) infusion) 
on the first treatment day during cycle 1 and immediately after end of VX-970 (M6620) infusion 
(within the next 120 minutes) on the first day of treatment during Cycle 1. For su bsequent cycles, ECG 
will be performed pre VX-970 (M6620) only on both days 2 and 5 (within the 120  minutes before the 
start of VX-970 (M6620) infusion).   
14  Only for women of child -bearing potential 
15  Only done in cycle 1  
16 Includes Albumin, Calcium, Magnesium (Mg), Phosphorus  
17  Approximately 4 weeks after treatment discontinuation 
18  Only done in cycles 1 and 2  
19  Will be collected pre-treatment on cycle 1 days 1 and 2; post-treatment on cycle 1 day 5 (within 3 
hours of completion of topotecan) a nd pre-treatment on cycle 2 day 1 as indicated in Section 5.1.6.  
20  Collection at this time point may be omitted  due to scheduling conflicts. 
21  Topotecan: may be collected at pre, end  of infusion (EOI), and 0.5, 1, 2, 4, 8, [ADDRESS_401533] EOI; VX-970 
(M6620) collected at pre, end of infusion (EOI), and 0.5, 1, 4, 8, 24, and [ADDRESS_401534] to patient scheduling;  ex., when the treatment is administered Mon-Fri, and may be 
omitted when the treatment runs through the weekend when the PK collection is not feasible. 
   
3.[ADDRESS_401535] dose of study therapy.  
3.5.1 Criteria for removal from protocol therapy  
• Progressive disease  
• Participant requests to be withdrawn from active therapy 
• Unacceptable Toxicity  as defined in S ection s 3.1.1  and 3.3 
• Toxicity related dose delay lasting longer than 21 days 
• Investigator discretion  
• Requirement for any of the prohibited study drugs as described in Section 4 an d 
Appendix B  (Strong Inhibitors and Inducers of CYP3A) 
• The subject becomes pregnant 
3.5.2 Off-Study Criteria  
• Participant lost to follow up  
• P articipant requests to be withdrawn from study 
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/2020  
 
29 
 • Death  
 
4 CONCOMITANT MEDICATIONS/MEASURES  
In vitro drug metabolism studies suggest that VX-970 (M6620) is a substrate of CYP3A and its 
systemic exposure may be affected by [CONTACT_325194]3A inhibitors 
and inducers. Please see a li st of CYP3A inhibitors and inducers in Appendix B  (Strong 
Inhibitors and Inducers of CYP3A) or at http://medicine.iupui.edu/clinphar m/ddis/ . Prior and 
conc omitant medication /food restri ctions are provided in Table 4. Based upon in vitro data, VX-
970 (M6620) is not a potent inhibitor or inducer of human CYP enzymes in isolated enzyme systems, t herefore the probability of VX-970 (M6620) interaction with other medications that are 
substrates of CYP metabolism is expected to be low.  
Table 4. Study Restrictions  
 
Medicati ons taken from [ADDRESS_401536] be re corded with indication, 
route of administration, and start and stop dates of a dministration. All subjects will be questioned 
about concomitant medication at each clinic visit.  
5 BIOSPECIMEN COLLECTI ON 
5.1 CORRELATIVE STUDIES FOR RESEARCH /PHARMACOKINETIC STUDIES  
Table 5. Summary of Collectio n of Correlative Samples 
Test/assay  Volume blood 
(approx) Type of 
tube  Collection point  
(+/- 5 days ) Location of 
specimen analysis  
Tumor 
(optional)  N/A N/A (1) Baseline (pretreatment)  
(2) C1 D3 before topotecan  
(3) Disease Progression  Trepel lab to p/u  
Hair Follicles  
(15-30) N/A N/A (1) Pretr eatment C1D1  
(2) C1D2 Post treatment  
(3) C1D3 Post treatment  Redon 
(To be done at same 
time as green top tubes ) 
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/2020  
 
30 
 Blood 
 6 mL Green Top  (1) Pretreatment C1D1  
(2) C1D2 Post treatment  
(3) C1D3 Pos t treatment  Redon (On ice)  
Circulating 
Nucleic Acids  10 mL  Lavender 
Top (1) Pretreat ment C1D1  
(2) Pretreatment C2D1  
(3) Disease Progression  
Trepel  
(Room temp erature)  Circulating 
Tumor Cells 10 mL (x2) Lavender 
Top (1) Pretreatment C1D1  
(2) Pretreatment C2D1  
(3) Disease Progress ion 
2.5 mL (x1) PAXgene 
RNA  
Immune 
Subsets (PBMC)  8 mL (x2)  CPT 
blue/black  (1) Pretreatment C1D1  
(2) Pretreatment C1D2  
(3) Posttreatment C1D5 w/in 3 hrs of topotecan  
(4) Pretreatment C2 D1 
PK topotecan  6 ml (x1) Sodium 
heparin tube C1D1: pre, end of infusion (EOI ), and 0.5, 
1, 2, 4, 8, [ADDRESS_401537] EOI (8 time points total).  
 Blood Processing Core 
([CONTACT_62583]) 
(On ice)  PK VX-970 
(M6620)  6 ml (x1) Sodium 
heparin tube C1D1 pre, end of infusion (EOI), and 0.5, 1, 4, 8, 24, and [ADDRESS_401538] EOI (8 time points total).  
 
5.1.1  γ-H2AX Detection in Tumor Biopsies, hair follicles and PBMC 
Phosphorylated H2AX (γ -H2AX) plays an important role in the recruitment and/or retention of 
DNA repair and checkpoint proteins such as BRCA1, MRE11/RAD50/NBS1 complex, MDC1 and 53BP1 (see Figure 1 ). DNA damage has been shown to increase H2AX phosphorylation in 
cancer cells following exposure to camptothecins. If VX- 970 (M6620)  is able to increase the 
degree of DNA damage due to topotecan, it may be detectab le by [CONTACT_305693] H2AX 
phosphorylation. We have successfully employed an immunofluorescence assay in previous clinical studies . We plan to study γ -H2AX incidences in patient PBMCs, hair follicles, and in 
tumor biopsies if there is readily accessible disease. Tumor and hair follicles will be obtained if patients are suitable candidates and willing to allow such sampling.  
This analysis will be explo ratory only and data will be used in planning biomarker endpoints in 
subsequent trials with the combination of VX- 970 (M6620)  and topotecan. This analysis will be 
exploratory only and data will be used in planning biomarker endpoints in subsequent trials w ith 
the combination of VX-970 (M6620) and topotecan. These studies are of interest in an early 
phase clinical trial and will be done primarily for Phase I part of the study. Additionally, these studies may be done in selected patients in Phase II.  
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/2020  
 
31 
 5.1.2 Sample C ollection  
[IP_ADDRESS]  Tumor tissue (optional)  
Paired tumor biopsies will be obtained by [CONTACT_325195] (pre- treatment), and after treatment  (on day 3 before 
topotecan), and at disease progression. Patient s on dose level [ADDRESS_401539] the second biopsy 
on day 3 (before topotecan) will serve as "controls" to show the induction of γ -H2AX with 
topotecan alone.  
The site of biopsy will be determined in discussion with interventional radiologist. If it can be 
safely obtained, 4 cores of tumor tissue will be collected. Two cores will be sent to pathology- one for confirmation of diagnosis and another will be used for making an FFPE block. The other 2 cores will be flash frozen at the time of biopsy.  When the patient is scheduled, the Trepel lab will be contact[INVESTIGATOR_530] [ by [CONTACT_20143] [EMAIL_2632] and Sunmin Lee [EMAIL_4969]
]. 
Interventional Radiology will call the lab at [PHONE_3305] when the patient arrives in IR and a lab member will be present at  Interventional Radiology for the procedure.  The cores will be 
flash frozen, 2D barcoded, and store d in liquid nitrogen.  
[IP_ADDRESS]  Blood samples  
Blood will be collected in a 6- ml green top tube at the following time points during cycle 1: Pre-
treatment on cycle [ADDRESS_401540] treatment on day 2 and 3 within 3 hours of completion of 
topotecan . When the patient is scheduled, the Trepel lab  will be contact[INVESTIGATOR_530]  [by [CONTACT_20143] 
[EMAIL_2632]  and Sunmin Lee [EMAIL_4969] ]. Blood from heparinized syringe 
will be mixed with a 1:1 ratio of room temperature PBS and layered over a 1:1 blood- PBS/Ficoll 
ratio in a conical centrifuge tube. The conical centrifuge tube should be centrifuged 25 minutes at room temperature at approximately 1000 rpm. The cell layer resting above the Ficoll and containing the peripheral blood mononuclear cells (PBMCs) will be aspi[INVESTIGATOR_325176] a 15 ml conical tube for washing in 15 ml PBS. PBMCs will be fixed with paraformaldehyde, spun onto a microscope slide and stain for γH2AX detection. Images from γ -H2AX- stained 
PBMCs will be recorded by [CONTACT_2329] a confocal microscope (
Figure 3, image at the top).  
[IP_ADDRESS]  Hair follicles  
Hair follicles will be collected at multiple time  points :  Pre -treatment  on cycle [ADDRESS_401541]. Aladjem’s lab (LMP/CCR/NCI, Bldg 37/ Rm 5056) to inform him when samples w ill be taken (Tel: [PHONE_6814] (L); 301 -760-6275 ( Cell); 
[EMAIL_3031]). [CONTACT_148430] will provide tubes for collecting the plucked hairs. The tubes 
contain ice cold PBS labeled with the date/time of sampling, the protocol, and the unique [ADDRESS_401542] follicle and sheath ( Figure 3, image in the middle). If it is determined by [INVESTIGATOR_124]. Redon 
that the hairs collected at the first [ADDRESS_401543]. Aladjem’s lab, 
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/[ADDRESS_401544] ed by [CONTACT_2329] a confocal microscope ( Figure 3, image at the 
bottom). 
 
 
Figure 3  
5.1.3 Genomic analysis  
Formalin fixed paraffin embedded tumor tissue (FFPE) from th e new biopsies and or from 
archived FFPE tissue from prior biopsies/surgical procedures will be sent to the Trepel  lab as 
described above . Genomic DNA and RNA will be extracted from the tumor. We will assess gene 
expression by [CONTACT_325196], NanoString or droplet digital PCR technology and also perform whole exome sequencing on pre- and post- treatment samples.   
The tumor tissue obtained before start of treatment will be used for the following assessments: γ -
H2AX (as described before), depending on the availability of tissue in the following sequence of priority 1. genes expression including the following genes: SLFN11, RAD51, RAD54L, BLM, TOP1, ATM, ATR, TOPBP1, POLQ, MCM2, FANCI, MGMT, ATAD5, ASCL1, ESRP1, CAV1, CCNE1, MYCL, MYC,  MYCN and RB1 expression, 2. If more tissue is available, it will 
be archived for whole exome sequencing.  
Tumor tissue obtained during and after treatment will be assessed for the following: γ -H2AX and 
gene expression studies.  
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/2020  
 
33 
 5.1.4 Circulating Nucleic Acids  
Circulating DNA will be isolated from plasma separated from peripheral blood drawn into 10- ml 
lavender top tubes pre- treatment on cycle 1 day 1, pre -treatment on cycle 2 day 1, and at disease 
progression. Mutations identified by [CONTACT_325197]. Mutations will be assessed by [CONTACT_325198], i.e. nested PCR, droplet digital PCR, Sanger sequencing, or next generation seq uencing on MiSeq (Illumina). These assessments will be performed by [CONTACT_325199].   
5.1.5 Circulating Tumor Cells  
Circulating tumor cells (CTCs), which can be prevalent in SCLC, present a readily accessible 
'liquid biopsy'. Peripheral blood will be collected ( pre-treatment on cycle 1 day 1, pre- treatment 
on cycle 2 day 1 and at disease progression) to correlate circulating tumor cell (CTC) levels at 
baseline or levels pre- and post-therapy with clinical response and survival. CTCs will be assessed using ferrof luidic enrichment and multiparameter flow cytometric detection. CTCs will 
be identified as viable, nucleated cells, that positively express one or more epi[INVESTIGATOR_258696]. CTCs will be enume rated and 
if sufficient, gene expression will be analyzed by [CONTACT_325200]. NanoString, whole transcriptome by [CONTACT_325201].  Peripheral blood will be drawn into two 10-ml lavender top tubes and one 2.5 ml PAXgene  RNA tube for each 
time point. These assessments will be performed by [CONTACT_325202]  
5.1.6 Immune Subsets  
Little is know n of the immunomodulatory effects of DNA damage-inducing cytotoxic therapy. 
Peripheral blood mononuclear cells (PBMC) obtained before and during treatment ( pre-treatment 
on cycle [ADDRESS_401545]-treatment on cycle 1 day 5 within 3 hours 
of completion of topotecan (collection at this time point may be omitted  due to scheduling 
conflicts) , and pre- treatment o n cycle 2 day 1) will be assessed by [CONTACT_325203], myeloid-derived suppressor cells, effector and exhausted CD4+ and CD8+ T -cells, and CD14+ monocytes. Assessment will include functional 
markers, i.e. PD- 1, Tim -3, CTLA -4, CD40, HLA- DR
, and/or PD -L1. Members of the lab will 
procure the peripheral blood samples, enter the samples in a secure patient database, process  the 
samples for viable cell storage, label each sample with a unique 2D barcode, and viably store the samples. They will prepare the samples for staining, stain and run the samples by [CONTACT_64392] (MACSQuant, Miltenyi Biotec, Bergisch Gladbach, DE), the data will be analyzed by [CONTACT_325204] v.X.0.6. Peripheral blood will be drawn into two 8- ml CPT 
citrate blue/black tubes for each time point. 
These assessments will be performed by [CONTACT_325202].  
5.1.[ADDRESS_401546] to scheduling, via 6mL sodium heparin tube (BD, Franklin 
Lakes, NJ) collected on the first daily dose on cycle 1 day 1 at the following time points: pre, end of infusion (EOI), and 0.5, 1, 2, 4, 8, [ADDRESS_401547] EOI (8 time -points total).  Bioanalytical 
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/2020  
 
34 
 measurements will be conducted on an ultra HPLC-MSMS system using an assay developed and 
validated by [CONTACT_251705]. 
VX-970 (M6620) 
Blood samples for the determination of plasma levels of VX-970 (M6620) may  be obtained from 
each patient , when feasible with regard to scheduling, via 6mL sodium heparin tube (BD, 
Franklin Lakes, NJ) collected on the first daily dose on cycle 1 day 2 at the  following time 
points: pre, end of infusion (EOI), and 0.5, 1, 4, 8, 24, and [ADDRESS_401548] EOI (8 time -points 
total).  Bioanalytical measurements will be conducted on an ultra HPLC-MSMS system using an assay developed and validated by [CONTACT_251705] (BPC) . 
This data will be used to monitor topotecan and VX -970 (M6620) plasma concentrations in order 
to correlate to pharmacodynamic endpoints, clinical response, and toxicity. 
The samples will be placed immediately on wet ice and refrigerated. The d ate and exact time of 
each blood draw should be recorded on the sample tube and the PK sheet.  
Please e- mail mailto: BPC at [EMAIL_1227]  at least 24 hours before transporting 
samples (the Friday before is preferred).  
For sample pi[INVESTIGATOR_9107], page 102-[ZIP_CODE]. For immediate help, call 240 -760-6180 (main blood processing core number) or, if no answer, 
[PHONE_1159] (main clinical pharmacology lab number). For questions regarding sample processing, contact [CONTACT_239947] e- mail. 
Upon arrival in the Blood Processing Core , samples will be centrifuged and the plasma 
transferred into cryovials for storage at -80 °C until the time of analysis. In addition, samples 
will be barcoded as described in Section  5.2.2. 
5.2 S
AMPLE STORAGE , TRACKING AND DISPOSITION  
All samples ( except the two cores of tissue which will be stored  in the Laboratory of Pathology 
and the PK samples which will be processed by [CONTACT_325205]) will be sent to and stored in Jane 
Trepel's Lab at NCI, Bldg 10, Room 12C208, Bethesda, MD. Place all samples at room temperature, phone the Trepel Lab at [PHONE_3305] and a laboratory member will come to pi[INVESTIGATOR_271563].  
Samples will be ordered in C RIS and tracked through a Clinical Trial Data Management system .  
Should a CRIS screen not be available, the CRIS downtime procedures will be followed. 
Samples will not be sent outside NIH without appropriate approvals and/or agreements, if required.  
All specimens obtain ed in the protocol are used as defined in the protocol. Any specimens that 
are remaining at the completion of the protocol will be stored in the conditions described below. 
The study will remain open so long as  sample or data analysis continues.  Samples fr om 
consenting subjects will be stored until they are no longer of scientific value or if a subject withdraws consent for their continued use, at which time they will be destroyed.  
 If the subject  withd raws consent the participants data will be excluded f rom future distributions, 
but data that have already been distributed for approved research use will not be able to be 
retrieved.  
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/[ADDRESS_401549]  ID, name, trial 
name/protocol number, date/time drawn, as w ell as b ox and freezer location. Subject 
demographic s associated with the clinical center patient  number are provided in the system. For 
each sample, there are notes associated with the processing method (delay in sample processing, storage conditions on the ward, etc.). Access to personally identifiable information (PII) is limited to the PI [INVESTIGATOR_167851].  
An additional layer of encryption will be added for samples undergoing genetic analysis in [CONTACT_325221]'s  lab where a separate clinically annotated unique sample ID will be generated linked w ith 
the sample ID in LabM atrix. As additional clinical information is generated and linked to the 
unique patient ID, it is also electronically linked via LabM atrix to the sample ID. [CONTACT_325221] 's lab 
will proceed with sample analysis and record data under the unique sample ID.  
Barcoded samples are stored in barcoded boxes in a locked freezer at either -20 or -80°C or in 
liquid nitrogen according to stability requirements. These freezers are located onsite, and access 
to stored clinical samples is restricted. Samples will be  stored until requested by a researcher 
named on the protocol. All requests are monitored and tracked in the LabM atrix System. All 
researchers are required to sign a form stating that the samples are only to be used for research purposes associated with this trial (as per the IRB approved protocol) and that any unused samples must be returned to the NCI. It is the responsibility of the NCI Principal Investigator [INVESTIGATOR_325177] a manner consistent with IRB approval. 
Samples will be stored in a freezer at either - 4° C or -70° C behind a door locked after working 
hours. Samples will be tracked by a designated member of the laboratory who is responsible f or 
notifying the PI [INVESTIGATOR_325178], for allocating the material to other 
members of the laboratory, for recording the disposition of the allocated material.   
5.2.2 Blood Processing Core (Laboratory of [CONTACT_195168]) 
[IP_ADDRESS]  Sample Data Colle ction 
All samples sent to the Blood Processing Core (BPC) will be barcoded, with data entered and 
stored in Labmatri x utilized by [CONTACT_74908]. This is a secure program, with access to L abmatri x 
limited to defined Figg lab  personnel, who are issued individual user accounts. Installation of 
Labmatri x is limited to computers specified by [INVESTIGATOR_124]. Figg. These computers all have a password 
restricted login screen.   
Labmatri x creat es a unique barcode ID for every sample and sample box, which cannot be traced 
back to patients without Labmatrix  access. The data recorded for each sampl e includes the 
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/2020  
 
36 
 patient ID, name, trial name/protocol number, time drawn, cycle time point, dose, material type, 
as well as box and freezer location. Patient demographics associated with the clinical center patient number are provided in the system. For each sample, there are notes associated with the processing method (delay in sample processing, storage conditions on the ward, etc.). 
[IP_ADDRESS]  Sample Storage and Destruction  
Barcoded samples are stored in barcoded boxes in a locked freezer at either -20 or -80°C 
according to stability requirements.  These freezers are located onsite in the BPC and offsite at 
NCI Frede rick Central Repository Services in Frederick, MD. Visitors to the laboratory are 
required to be accompanied by [CONTACT_79922].  
Access to  stored clinical samples is restricted. Samples will be stored until requested by a 
researcher named on  the protocol. All requests are monitored and tracked in Labmatrix. All 
researchers are required to sign a form stating that the samples are only to be use d for research 
purposes associated with this trial (as per the IRB approved protocol) and that any unused 
samples must be returned to the BPC. It is the responsibility of the NCI Principal Investigator [INVESTIGATOR_325179] g used in a manner consistent with IRB approval. 
Following completion of this study, samples will remain in sto rage as detailed above. Access to 
these samples will only be granted following IRB approval of an additional protocol, granting the rights to use the mat erial.  
If, at any time, a patient withdraws from the study and does not wish for their existing samples to be utilized, the individual must provide a written request. Following receipt of this request, the samples will be destroyed (or returned to the pat ient, if so requested) . Any samples lost (in transit 
or by a researcher) or destroyed due to unknown sample integrity (i.e. broken freezer allows for extensive sample thawing, etc.) will be reported per  7.2.1. 
Samp le barcodes are linked to patient demographics and limited clinical information. This 
information will only be provided to investigators listed on this protocol, via registered use of the Labmatri x. It is critical that the sample remains linked to patient information such as race, age, 
dates of diagnosis and death, and histological information about the tumor, in order to correlate genotype with these variables. 
5.2.3 Future Use/IRB Reporting/Protocol Com pletion/Sample Destruction  
Blood and tissue specimens collected in the course of this research project may be banked and 
used in the future to investigate new scie ntific questions related to this study , including optional 
germline analysis .  Howev er, this research may only be done if the risks of the new questions 
were covered in the consent document and the proposed research has undergone prospective IRB review and  approval.  If new risks are associated with the research (e.g., analysis of germ li ne 
genet ic mutations.) the Principal Investigator [INVESTIGATOR_325180].  
Following completion of this study, sample s will remain in storage as detailed above only for 
those subjects that agreed to future use in the Optional Studies section of the consent form.  Access  to these samples will only be granted following IRB approval of an additional protocol, 
granting the rights to use the material.  Currently, there is no plan to use these samples outside of the use described in the protocol.  
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/[ADDRESS_401550] withdraws consent the participant’ s data will be excluded from future 
distributions, but data that have already been distributed for approved research use will not be 
able to be retrieved.  
 The PI [INVESTIGATOR_325181] a deviation.  Reporting 
will be per the requirements of section  7.2. 
5.3 SAMPLES FOR GENETIC /GENOMIC  ANALYSIS  
5.3.1 Description of the scope of geneti c/genomic analysis  
One of the exploratory endpoints of this prot ocol is to characterize mutations which predict 
response and changes associated with the development of chemoresistance. To this end, whole and targeted exome sequencing will be performed on tumor samples collected pre -treatment 
and/or post-progression.  S ince analysis of germline variants is essential to fully characterize the 
somatic mutations  identified in exome sequencing, these assays will involve both somatic and 
germline DNA.  
5.3.2 Descriptio n of how privacy and confidentiality of medical information/biol ogical 
specimens will be maximized  
Please refer to Section 5.2. 
5.3.[ADDRESS_401551] adve rse 
consequences for subjects or damage their financial standing, employability, insurability or reputation.  The informed consent includes the appropriate coverage and restrictions of the 
Certificate of Confidentiality.  
5.3.4 Management of Results  
Subjects w ill be contact[CONTACT_35114] a clinically actionable gene variant is discovered. Clinically 
actionable findings for the purpose of this study are defined as disorders appearing in the American Co llege of M edical Genetics and Genomics recommendations for the return of 
incidental findings that is current at the time of primary analysis. (A list of current guidelines is maintained on the CCR intranet: https://ccrod.cancer.gov/conf luence/display/CCRCRO/Incidental+Findings+Lists
).  Subjects 
will be contact[CONTACT_148408] a r equest to provide a blood sample to be sent to a CLIA 
certified laboratory. If the r esearch findings are verified in the CLIA certified lab, the subject 
will be offered the opportunity to come to NIH (at our expense) to have genetic education and 
counseling to explain this result.  If the subject does not want to come to NIH, a referral t o a 
local genetic healthcare provider will be provided (at their expense ). 
This is the only time during the course of the study that incidental findings will be returned. No interrogations regarding clinically actionable findings will be made after the pri mary anal ysis. 
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/[ADDRESS_401552] protected 
electronic system  (C3D  and L abmatrix ) and ensuring data accuracy, consistency and timeliness. 
The pri ncipal i nvestigator, associate investigators/research nurses and/or a contracted data 
manager will assist with the data management efforts.  All data obtained during the co nduct of 
the protocol will be kept in secure network drives or in approved alternati ve sites  that comply 
with NIH security standards. Primary and final a nalyzed data will have identifiers so that 
research data can be attributed to an individual human subje ct participant.  
All AEs, including clinically significant abnormal findings on laboratory evaluations, regardless 
of severity, will be followed until ret urn to baseline or stabilization of event.   
Document AEs from the first study intervention, Study Day [ADDRESS_401553] 
administration of investigational agent/intervention and have an attribution of at least possibly related to the agent/intervention should be recorded.  
An abnormal laboratory value will be considered an AE if the laboratory abnormality is 
characterized by [CONTACT_39132]: 
• Result s in discontinuation from the study 
• Is associated with clinical signs or symptoms  
• Requires treatment or any other therapeutic intervention  
• Is associated with death or another serious adverse event, including hospi[INVESTIGATOR_059].  
• Is judged by [CONTACT_325206] 
• If any abnormal laboratory result is considered clinically signif icant, the investigator will 
provide details about the action taken with respect to the test  drug and about the subject ’s 
outcome. 
End of study procedure s: Data will be stored according to HHS, FDA regulations, and NIH 
Intramural Records Retention Schedule as applicable.  
Loss or destruction of data: Should we become aware that a major b reach in our plan to protect 
subject confidentiality and trial data ha s occurred, this will be reported expeditiously per 
requirements in section 7.2.1.  6.1.1 Genomic Data Sharing Plan  
Unlinked genomic data will be deposited in public genomic databases such as dbGaP in 
compliance with the NIH Genomic Data Sharing Policy. 
6.2 R
ESPONSE CRITERIA  
For the purposes of this study, subjects should be re- evaluated for response every 2 cycles .  In 
addition to a baseline scan, confirmatory scans should also be obtained 6 weeks  (not less than 4) 
following initial documentation of objective response. 
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/2020  
 
39 
 Response and progression will be evaluated in this study using the new international criteria 
proposed by [CONTACT_325207] C riteria in Solid Tumors (RECIST) guideline 
(version 1.1) [ 10].  Changes in the largest diameter (unidimensional measurement) of the tumor 
lesions and the shortest diameter in the case of malignant lymph nodes are used in t he RECIST 
criteria.  
6.2.1 Definitions  
Evaluable for toxicity:  All su bject s will be evaluable for toxicity from the time of their first 
treatment with t opotecan. 
Evaluab le for objective response: Only those subject s who have measurable disease present a t 
baseli ne, have received at least one cycle of therapy, and have had  their disease re- evaluated will 
be considered evaluable for response.  These subject s will have their response classified 
according to the definitions stated below.  (Note:  Subject s who exhibit objective disease 
progression prior to the end of cycle 1 wi ll also be considered evaluable.)  
Evaluable Non- Target Disease Response:  Subject s who have lesions pre sent at baseline that are 
evaluable but do not meet the definitions of measurable di sease, h ave received at least one cycle 
of therapy, and have had thei r disease re- evaluated will be considered evaluable for non -target 
disease.  The response assessment is  based on the presence, absence, or unequivocal progression 
of the lesions.  
6.2.2 Diseas e Paramet ers 
Measurable disease:  Measurable lesions are defined as th ose that can be accurately measured in 
at least one dimension (longest diameter to be recorded) as: 
• By [CONTACT_13190] x -ray: >20 mm  
• By [CONTACT_3610]:  
o Scan slice thickness 5 mm or under as >[ADDRESS_401554] scan  
o Scan slice thickness >5 mm: double the slice thickness  
• With  calipers on clinical exam  >[ADDRESS_401555] be recorded in millimeters  (or decimal fractions of centimeters).  
Malignant lymph nodes.  To be considered pathologically enlarged and measurable, a lymph 
node must be >[ADDRESS_401556] scan (CT scan slice thickness 
recommended to be no greater than 5 mm).  At baseline and in follow-up, only the short axis will be measured and followed. 
Non-measurable d isease.  A ll other lesions (or sites of disease), including small lesions (longest 
diameter <10 mm or pathological lymph nodes with ≥ 10 to <15 mm short axis), are considered 
non-measurable disease.  Bone lesions, leptomeningeal disease, ascites, pleural/per icardial  
effusions, lymphangitis cutis/pulmonitis, inflammatory breas t disease, and abdominal masses 
(not followed by [CONTACT_462]), are considered as non- measurable.  
Note:  Cystic lesions that meet the criteria for radiographically defined simple cysts shou ld not 
be considered as malignant lesions (neither measurable nor non-measurable) since they are, by [CONTACT_108], simple cysts.  
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/2020  
 
40 
 ‘Cystic lesions’ thought to represent cystic metastases can be considered as measurable lesions, 
if they meet the definition of me asurabil ity described above. However, if non- cystic lesions  are 
present in the same subject , these are preferred for selection as target lesions.  
Target lesions.   All measurable lesions up to a maximum of 2 lesions per organ and 5 lesions in 
total, repres entative of all involved organs, should be identified as target lesion s and recorded 
and measured at b aseline.  Target lesions should be selected on the basis of their size (lesions 
with the longest diameter), be representative of all involved organs, but in addition should be those that lend themselves to reproducible repeated measurements.  It may be the case that, on occasion, the largest lesion does not lend itself to reproducible measurement in which circumstance the next largest lesion which can be measured reproducibly should be selected.  A sum of the diameters (longest for non-nodal lesions, short axis for nodal lesions) for all target lesions will be calculated and reported as the baseline sum diameters.  If lymph nodes are to be included in the sum, then only the short axis is added into the sum.  The baseline sum diameters will be used as reference to further characterize any objective tumor regression in the measurable dimension of the disease. 
Non-target lesions.  All other lesions (or sites of disease) including any measurable lesions over 
and above the 5 target lesions should be identified as non- target lesions and should also be 
recorded at baseline.  Measurements of these lesions are not required, but the presence, absence, or in rare cases u nequivocal progression of each should be noted throughout follow-up.  
6.2.3 Methods for Evaluation of Measur able Disease  
All measurements should be taken and recorded in metric notation using a ruler or calipers.  All baseline evaluations should be performed as closely as possible to the beginning of treatment and never more than 4 weeks before the beginning of the treatment.  
The same method of assessment and the same technique should be used to characterize each identified and reported lesion at baseline and during follow- up. Imaging-based evaluation is 
preferred to evaluation by [CONTACT_460](s) being followed cannot be imaged but are assessable by [CONTACT_461].  
Clinical lesions :  Clinical lesions will only be considered measurable when  they are superficial 
(e.g., skin nodules and palpable lymph nodes) and ≥10 mm diameter as assessed using calipers 
(e.g., skin nodules).  In the case of skin lesions, documentation by [CONTACT_6775], including a ruler to estimate the size of the lesion,  is recom mended.  
Chest x -ray:  Lesions on chest x- ray are acceptable as measurable lesions when they are clearly 
defined and surrounded by [CONTACT_6776].  However, CT is preferable.  
Conventional CT and MRI:  This guideline has defined measurability of lesions on CT scan 
based on the assumption that CT slice thickness is [ADDRESS_401557] sli ce thickness 
greater than 5 mm, the minimum size for a measurable lesion should be twice the slice thickness.  MRI is also acceptable in certain situation s (e.g. for body scans).   
Use of MRI remains a complex issue.  MRI has excellent contrast, spatial, a nd temporal 
resolution; however, there are many image acquisition variables involved in MRI, which greatly impact image quality, lesion conspi[INVESTIGATOR_3934], and me asuremen t.  Furthermore, the availability of 
MRI is variable globally.  As with CT, if an MRI is performed, the technical specifications of the scanning sequences used should be optimized for the evaluation of the type and site of disease.  
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/[ADDRESS_401558] , the modality used at follow-up should be the same as was us ed at 
baseline and the lesions should be measured/assessed on the same pulse sequence.  It is beyond 
the scope of the RECIST guidelines to prescribe specific MRI pulse sequence parameter s for all  
scanners, body parts, and diseases.  Ideally, the same type of scanner should be used and the image acquisition protocol should be followed as closely as possible to prior scans.  Body scans should be performed with breath-hold scanning techniques, if poss ible. 
PET- CT:  At present, the low dose or attenuation correction CT portion of a combined P ET-CT 
is not always of optimal diagnostic CT quality for use with RECIST measurements.  However, if the site can document that the CT performed as part of a PET -CT is of identical diagnostic 
quality to a diagnostic CT (with IV and oral contrast), then the CT portion of the PET- CT can be 
used for RECIST measurements and can be used interchangeably with conventional CT in accurately measuring cancer lesions o ver time.   Note, however, that the PET portion of the CT 
introduces additional data which may bias an investigator if it is not routinely or serially performed.   
Ultrasound:  Ultrasound is not useful in assessment of lesion size and should not be used as a 
method of measurement.  Ultrasound examinations cannot be reproduced in their entirety for independe nt review at a later date and, because they are operator dependent, it cannot be 
guaranteed that the same technique and measurements will be taken from one assessm ent to the 
next.  If new lesions are identified by [CONTACT_12153], confirmation by [CONTACT_12154].  If there is concern about radiation exposure at CT, MRI may be used instead of CT in selected instances.  
Endoscopy, Laparoscopy:  The utilization of these techniques for objective tumor evaluation is 
not advised.  However, such techniques may be useful to confirm complete pathological response when biopsies are obtained or to determine relapse in trials where recurrence f ollowing 
complete response (CR) or surgical resection is an endpoint. 
Tumor markers :  Tumor markers al one cannot be used to assess response.  If markers are initially 
above the upper normal limit, they must normalize for a subject to be considered in comple te 
clinical response.  Specific guidelines for both CA-125 response ( in recurrent ovarian cancer) 
and PSA response (in recurrent prostate cancer) have been published [ 11-13 ].  In addition, the 
Gynecologic Cancer Intergroup has developed CA-[ADDRESS_401559]- line trials in ovarian cancer [ 14]. 
Cytology, Histology:  These t echniques can be used to differentiate between partial respo nses 
(PR) and complete responses (CR) in rare cases (e.g., residual lesions in tumor types, such as germ cell tumors, where known residual benign tumors can remain). 
The cytological confi rmation of the neoplastic origin of any effusion that appears or wors ens 
during treatment when the me asurable tumor has met criteria for response or stable disease is 
mandatory to differentiate between response or stable disease (an effusion may be a side effect o f 
the treatment) and progressive disease.  
FDG -PET:  While FDG -PET response assessments need additional study, it is sometimes 
reasonable to incorporate the use of FDG-PET scanning to complement CT scanning in assessment of progression (particularly possible 'new' disease).  New lesions on the basis of FDG -PET imagin g can be identified according to the following algorithm:  
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/2020  
 
42 
 a. Negative FDG -PET at baseline, with a positive FDG -PET at follow -up is a sign of 
PD based on a new lesion. 
b. No FDG -PET at baselin e and a p ositive FDG -PET at follow -up:  If the positive FDG-
PET at fol low-up corresponds to a new site of disease confirmed by [CONTACT_4654], this is PD.  If 
the positive FDG- PET at follow -up is not confirmed as a new site of disease on CT, 
additional follow-up CT  sc ans are needed to determine if there is truly progression 
occurring a t that site (if so, the date of PD will be the date of the initial abnormal 
FDG -PET scan).  If the positive FDG- PET at follow -up corresponds to a pre-existing 
site of disease on CT that is not progressing on the basis of the anatomic images, this 
is not PD. 
c. FDG -PET may be used to upgrade a response to a CR in a manner similar to a biopsy 
in cases where a residual radiographic abnormality is thought to represent fibrosis or scarring.  The use of FD G-PET in this circumstance should be prospectively 
described in the protocol and supported by [CONTACT_4623] -specific medical literature for the 
indication.  However, it must be acknowledged that both approaches may lead to false positive CR due to limitations of FDG -PET and biopsy resolution/sensitivity. 
 Note:  A ‘positive’ FDG -PET scan lesion means on e which is FDG avid with an uptake greater 
than twice that of the surrounding tissue on the attenuation corrected image. 
6.2.4 Response Criteria  
[IP_ADDRESS]  Evaluation of T arget Les ions 
Complete Response (CR) : Disappearance of all target lesi ons.  Any pathological lymph nodes 
(whether target or non-target) must have reduction in short axis to <10 mm. 
Partial Response (PR) : At least a 30% decrease in the sum of the diameters of target  lesions, 
taking as reference the baseline sum of diameters.  
Progressive Disease (PD) : At lea st a 20% increase in the sum of the diameters of target lesions, 
taking as reference the smallest sum on study (this includes the baseline sum if that is t he 
smallest on study).  In addition to the relative increase of 20%, the sum must also demonstrate an  
absolute increase of at least 5 mm.  (Note:  the appearance of one or more new lesions is also 
considered progressions). 
Stable Disease (SD) : Neither suf ficient s hrinkage to qualify for PR nor sufficient increase to 
qualify for PD, taking as reference the smallest sum of diameters while on study. 
[IP_ADDRESS]  Evaluation of Non-Target Lesions  
Complete Response (CR) : Disappearance of all non -target lesions and normalizat ion of tum or 
marker level.  All lymph nodes must be non-pathological in size (<10 mm short axis). 
Note :  If tumor markers are initially above the upper normal limit, they must normalize for a 
subject  to be considered in complete clinical response. 
Non-CR/N on-PD: Persistence of one or more non- target lesion(s) and/or maintena nce of tumor 
marker level above the normal limits.  
Progressive Disease (PD) : Appearance of one or more new lesions and/or unequivocal 
progression of existing non-target lesions.  Unequivocal progr ession  should not normally trump 
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/[ADDRESS_401560] be representative of overall  disease status change, not a single lesion 
increase.     
Although a clear progression of “non-target” lesions only is exceptional, the opi[INVESTIGATOR_12999], and the progression status should be 
confirmed a t a later time by [CONTACT_463] (or Principal Investigator).  
[IP_ADDRESS]  Evaluation of Best Overall Response  
The best overall response is the best response recorded from th e start of the treatment until 
disease progression/recurrence (taking as reference for progre ssive disease the smallest 
measurements recorded since the treatment started).  The subject 's best response assignment will 
depend on the achievement of both measu rement and confirmation criteria.  
Table 6. For Subjects with Measurable Disease (i.e., Target Disease)  
Target 
Lesions  Non-Target 
Lesions  New 
Lesions  Overall 
Response  Best Overall Response when 
Confirmation is Required*  
CR CR No CR >4 wks. Confirmation** 
CR Non-
CR/Non -PD No PR 
>4 wks. Confirmation** CR Not 
evaluated  No PR 
PR Non-
CR/Non -
PD/not 
evaluated  No PR 
SD Non-
CR/Non -
PD/not 
evaluated  No SD 
Documented at least once >4 
wks. from baseline** 
PD Any Yes or 
No PD 
no prior SD, PR or CR  Any PD*** Yes or 
No PD 
Any Any Yes PD 
* See RECI ST 1.1 manuscript for further details on what is evidence of a new lesion.  
** Only for non-randomized trials with response as primary endpoint.  
*** In exceptional circumstances, unequivo cal progr ession in non -target lesions may be accepted as 
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/2020  
 
44 
 disease progr ession.  
Note : Subject s with a gl obal deterioration of health status requiring discontinuation of treatment without 
objective evidence of disease progression at that time should be report ed as “ symptomatic 
deterioration.”   Every effort should be made to document the objective progression even after 
discontinuation of treatment.  
 
Table 7. For Subjects with Non- Measurable Disease (i.e., Non -Target Disease)  
Non-Target  Lesions  New Lesions  Overall Response 
CR No CR 
Non-CR/non- PD No Non-CR/non- PD* 
Not all evaluated  No not evaluated  
Unequivocal PD Yes or No  PD 
Any Yes PD 
* ‘Non -CR/non- PD’ is preferred over ‘stable disease’ for non -target disease since SD is increasin gly used 
as an endpoint for assessment of efficacy in some trials so t o assign this category when no l esions can be 
measured is not advised  
6.2.5 Duration of Response 
Duration of overall response:  The duration of overall response is measured from the time 
meas urement cr iteria are met for CR or PR (whichever is first recorded) un til the first date that 
recurren t or progressive disease is objectively documented (taking as reference for progressive 
disease the smallest measurements recorded since the treatment star ted). 
The duration of overall CR is measured from the time measurement criteria are first met for CR 
until the first date that progressive disease is objectively documented.   
Duration of stable disease :  Stable disease is measured from the start of the tr eatment u ntil the 
criteria for progression are met, taking as reference the smallest measurements recorded since the 
treatment started, including the baseline measurements.  
6.2.[ADDRESS_401561]  while on the study.  The descri ptions and grading scales found in the revised NCI 
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/2020  
 
45 
 Common Terminology Criteria for Adverse Events (CTCAE) version 4.[ADDRESS_401562] CAE version 
4.0.  A copy of the CTCAE version 4.0 can be downloaded from the CTEP web site (http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40
).  
7 NIH RE PORTING REQUIREMENTS / DATA AND SAFETY MONITORING PLAN 
7.1 DEFINITIONS  
Please refer to definitions provided in Policy 801: Reporting Research Events found here . 
7.2 OHSRP  OFFICE OF COMPLIANCE AND TRAINING / IRB  REPORTING  
7.2.1 Expedited Reporting  
Please refer to the reporting requirements in Policy 801: Reporting Research Events and Policy 
802 Non -Compliance Human Subjects Research found here .  
Note: Only IND Safety Reports that meet the definition of an unanticipated problem will need to be reported  per these polic ies. 
7.2.2 IRB Requirements for PI [INVESTIGATOR_79875] 801: Reporting Research Events found here
. 
7.[ADDRESS_401563]. 
Dahut at N [EMAIL_6357]
 within one business day of learning of the death. 
7.4 NIH  REQUIRED DATA AND SAFETY MONITORING PLAN 
7.4.1 Principal Investigator/Research Team  
The clinical research team will  meet on a weekly  basis  when subjects are being actively treated 
on the trial to discuss each subject . Decisions about dose level enrollment and dose escalation if 
applicable will be made based on the toxicity data from prior subjects.  All data will be co llected i n a timely manner and reviewed by [CONTACT_1716][INVESTIGATOR_1660] [INVESTIGATOR_1660] a lead 
associate investigato r. Events meeting requirements for expedited reporting as described in 
section 7.2.[ADDRESS_401564] or supervise the 
investigation and provide appropriate de legation  of responsibilities to other members of the 
research staff.  
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/[ADDRESS_401565] a causal relationship with this 
treatment. An adverse event (AE) can therefore b e any unfavorable and unintended sign 
(including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (inv estigatio nal) product, whether or not related to the medicinal 
(investigational) product (ICH E6 (R2)). 
8.1.2 Serious Adverse Event (SAE)  
An adverse event or suspected adverse reaction is considered serious if in the view of the 
investigator or the sponsor, it re sults in  any of the following: 
• Death,  
• A life -threatening adverse event (see 8.1.3) 
• Inpatient hospi[INVESTIGATOR_1081] 
o A hospi[INVESTIGATOR_059]/admission that is pre -planned (i.e., elect ive or scheduled surgery 
arranged prior to the start of the study), a planned hospi[INVESTIGATOR_5912]- existing 
condition, or a procedure required by [CONTACT_760], without a serious deterioration in 
health, is not considered a serious adverse event. 
o A hospi [INVESTIGATOR_5186] n/admission that is solely driven by [CONTACT_105]-medical reasons (e.g., 
hospi[INVESTIGATOR_138707]) is not considered a serious adverse event.  
o Emergency room visits or stays in observation units that do not result in admission to the hospi[INVESTIGATOR_62489] a serious adverse event. The reason for seeking medical care should be eval uated for meeting one of the other serious criteria. 
• Persistent or significant incapacity or substantial disruption of the ability to conduct normal life  functions 
• A congenital anoma ly/birth defect.  
• Important medical events that may not result in death, be life -threatening, or require 
hospi[INVESTIGATOR_3767] a serious adverse drug experience when, based upon appropriate medical judgment, they may  jeopardiz e the patient or su bject and may require 
medical or surgical intervention to prevent one of the outcomes listed in this definition.  
8.1.3 Life-threatening  
An adverse event or suspected adverse reaction is considered "li fe-threatening" if, in the view of 
either the investigator or sponsor, its occurrence place s the patient or subject at immediate risk of 
death. It does not include an adverse event or suspected adverse reaction that, had it occurred in a more severe form, might have caused death. (21CFR312.32). 
8.1.4 Severity  
The severity  of each Adverse Event will be assessed utilizing the CTCAE version 4. 
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/[ADDRESS_401566] assessed using the terms:  related or not 
related.   
• Related  – There is a reasonab le possibility that the study product caused the adverse 
event. Reasonable possibility means that there is evidence to suggest a causal relationship between the study product and the adverse event. 
• Not Related  – Th ere is not  a reasonable possibili ty that the administration o f the study 
product caused the event.  
8.[ADDRESS_401567] and alternate etiology (if not re lated to study product), dat e of 
resolution of the event, seriousness and outcome. The assessment of severity and relationship to the study product will be done only by [CONTACT_8703] a diagnosis and listed on the Form FDA 1572 as the site principal inv estigator or sub-investigator.  AEs 
occurring during the collection and reporting period will be documented appropriately regardless of relationship.  AEs will be followed through resolution. 
SAE s will be: 
• Assessed for severity  and relat ionship to study product and alternate etiology (if not 
related to study product) by a licensed study physician listed on the Form FDA 1572 as 
the site principal investigator [INVESTIGATOR_11637]-investigator. 
• Recorded on the appropriate SAE report form, the me dical record and captured in the 
clinical database.  
• Followed through resolution by a licensed study physician listed on the Form FDA [ADDRESS_401568] be submitted immediately (within 24 hours 
of awareness) to OSRO Safety using the CCR SAE report form. 
All SAE reporting must include the el ements described in 8.2. 
SAE reports  will be submitted to the Center for Cancer Research (CCR) at:  
[EMAIL_1230]  and to the CCR PI [INVESTIGATOR_32528].  CCR SAE r eport form 
and instructions can be found at: 
https://ccrod.cancer.gov/confluence/pages/viewp age.action?pageId=157942842 
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/2020  
 
48 
 Following the assessment of the SAE by [CONTACT_62554], other supporting documentation of the event 
may be requested by [CONTACT_62555]. 
8.4 SAFETY REPORTING CRITERIA TO THE PHARMACEUTICAL COLLABORATO RS 
8.4.1 EMD -Serono 
[IP_ADDRESS]  The following reportable events must be submitted to EMD Serono  by [CONTACT_325208]  2 business days or 3 
calendar days (whichever comes first) using the mandatory MedWatch for m 3500a or equivalent. 
The Sponsor will assume responsibility for submitting the report able event(s)  below to EMD 
Serono a s well as en suring tha t any local reportin g requirements are completed in parallel.  
• Serious Adverse Events (refer to section  8.1.2) 
• Exposure during Pregnancy or Breastfeeding (even if not associated with an adver se 
event)  
[IP_ADDRESS]   The followi ng reportable events  must be submitted to EMD Serono  by [CONTACT_978] [INVESTIGATOR_126985]   
• Occupational exposure (even if not a ssociated with an adverse event)  
• Potential drug-induced liver injury (Hy’s Law cases): T hese events are considered 
important medical e vents and should be reported as SAEs.   
• In addition, all AEs will be collected in tabulated form and reported to EMD Serono as 
outlined in the Collaborative Agreement.  
• Reporting of Overdose  of M 6620: An overdose is defined as any dose 5% greater than 
the h ighest dose included in the cli nical trial protoco l. Any overdose must be recorded in 
the trial medication section of the eCRF. For monitoring purposes, any case of overdose, whether or not associated with an AE (serious or non-serious), must be reported. Th ere 
are n o known symptoms of M6620 overdose to date. The Investigator should monitor 
closely for AEs should an overdose occur and use his or her clinical judgment in providing symptomatic/ supportive care as  medically indicated. There is no known 
antidote  for M 6620. 
[IP_ADDRESS]  Contact [CONTACT_148411]: 
Fax: [PHONE_3306] 
OR 
E-mail: [EMAIL_3033]  
Specifying: 
PROTOCOL Number and/or Title  
EMD Sero no assigned Study Number : MS201923-[ADDRESS_401569] Number  
SITE N umber/PI [INVESTIGATOR_325182] d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/2020  
 
49 
 8.5 SAE/ONSET  DATE  REPORTING PREGNANCY  
8.5.1 Maternal  exposure  
If a patient becomes pregnant during the course of the study, the study treatment should be 
discontinued immediately, and the pregnancy rep orted to the Sponsor no later  than 24 hours of 
when the Investigator becomes aware of it. The Investigator should notify the Sponsor no later 
than 24 hours of when the outcome of the Pregnancy become known, 
Pregnancy itself is not regarded as an SAE. Ho wever, conge nital abnormalities or birth defects 
and spontaneous miscarriages that meet serious criteria ( 8.1.2) should be reported as SAEs .  
The outcome of all pregn ancies (spontaneous miscarriage, elective terminat ion, ectopic 
pregnancy, normal birth, or congenital abnormality) should be followed up and documented. 8.5.2 Paternal exposure 
Male patients should refrain from fathering a child or donating sperm during the study and for (6 
months) after the last d ose of VX-970 (M6620). 
Pregnancy of the pa tient’s partner is not considered to be an AE. However, the outcome of all 
pregnancies (spontaneous miscarriage, elective termination, ectopic pregnancy, normal birth, or congenital abnormality) occurring from the date of the f irst dose until (6 months) after the last 
dose should, if possible, be followed up and documented. 
8.[ADDRESS_401570] and the adverse event.  CCR will notify FDA and all par ticipating investigators (i.e., all 
investigators to whom the sponsor is providing drug under its INDs or under any investigator’s IND) in an IND safety report of potential serious risks from clinical trials o r any other source, as 
soon as possible, in accordance to [ADDRESS_401571] annually in a summary format.  
9 CLINICAL  MONITORING  
As a sponsor for clinical trials, FDA regulations require the CCR to maintain a monitoring program. The CCR ’s program  allows for confirmation of: stu dy data, specifical ly data that could 
affect the interpretation of primary  and secondary study endpoints; adherence to the protocol, 
regulations, ICH E6 and SOPs; and human subjects protection. This is done through independent 
verificat ion of study data with source documentation focusing on: 
• Informed consent process 
• Eligibility confirmation  
• Drug  administration and accountability  
• Adverse events monitoring 
• Response assessment.  
The monitoring program also extends to multi- site r esearch when  the CCR is the coordinating 
center.   
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/[ADDRESS_401572]. 
10 STATISTICAL  CONSIDERATIONS    
Primary Objectives:  
• Phase I : To identify the maximum tolerated dose (MTD) of topotecan in combination 
with VX-970 (M6620). 
• Phase II: To assess the efficacy with respect to clinical  response rate of a combinati on of 
topotecan and VX -970 (M6620) in previously treated subject s with SCLC  and extra-
pulmonary small cell carcinomas . 
Secondary Objectives:  
• To determine the progression- free survival (PFS) and overall survival (OS ) of a 
combination of topotecan and VX-970 (M6620) in SCLC.  
• To assess safety and tolerability of a combination of topotecan and VX-970 (M6620). 
• To identify pharmacodynamic markers of response. 
• To assess duration of response to the combination in both platinum sensi tive and 
refractory patients.  
Exploratory Objectives:  
• Assess target modulation by [CONTACT_94273]-970 (M6620)  
• Characterize gene expres sion and mutations which predict response and changes 
associated with development of chemoresistance  
• Characterize CTC and ct- DNA  
The ini tial portion of the trial will be a phase I dose escalation study using a standard 3 + 3 
design to determine a MTD over increasing dose levels of VX- 970 (M6620) . The phase II trial 
will be conducted using a Simon two -stage Minimax design in order to rul e out an una cceptably 
low 10% re sponse rate (p0=0.10) in favor of a targeted response rate of 30% (p1=0.30). Based 
on historical controls, actually observing a response rate of 20% would be considered clinic ally 
meaningful in this setting. With a lpha=0.10 and  beta = 0.10, the study will initially enroll [ADDRESS_401573] s. If there were 2 -4 responses in 25 subjects, this would not be 
considered promising in this population. If there were 5 or mor e subjects  of the 25 (20.0%) who 
have a response, this would be sufficiently interesting to warrant further study of this 
combination in a future randomized trial of topotecan vs. topotecan+ VX -970 (M6620). T he 
probability of early termination is 51.5% if the true response rate were 10%.  In addition, with 
amendment B, up to 15 patients with extrapulmonary small cell cancers  may be enrolled on the 
protocol. Response rates of these patients will not be included in the pr imary statistical an alysis 
and will be described in an exploratory manner.  
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/[ADDRESS_401574] follow-up. 
Progression free survival will be determined from the on-study date unt il date of progression. 
The probabilities of surviv al and of progression free survival will be determined by [CONTACT_8761]-
Meier method.  
10.1 DETERMINATION OF SAMPLE SIZE 
The theoretical maximum number of subjects required to determine the MTD in the phase I 
portion of the study is 24 subjects (6 per dose level), although it is expected that as few as [ADDRESS_401575] their  response rate reported along with 
appropriate confidence intervals.  
We anticipate t hat it will take approximately 4 years  to accrue 40 evaluable subjects to the pha se 
II portion of the trial.  
11 COLLABORATIVE AGREEMENTS   
11.1 C
OOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT (CRADA)  
The study drug VX-970 (M6620) was initially  provided under a CRA DA (#2999) between the 
manufacturer, Vertex, and the Thoracic Gastrointestinal On cology Branch, Nati onal Cancer 
Institute . 
Amendment [ADDRESS_401576] SELECTIO N 
As previous ly descri bed, the subjects for thi s study will include all subjects who meet the 
eligibility criteria outlined in sectio n 2.1.  No gender, racial, or ethnic groups will be excluded 
from participation in this trial.   
12.2 PARTICIPATI ON OF CHILDREN  
Because no dos ing adverse event data are currently available on the use of topotecan in 
combination with VX-970 (M6620) in subjects <[ADDRESS_401577] benefit from 
research participation (section  12.4) , all subjects  ≥ age 18 will be offered the opportunity to fill 
in their wishes for research and care,  and assign a substitute decision maker on the “NI H 
Advance Directive for Health Care and Medical Research Participation” form so that another 
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/2020  
 
52 
 person can make decisions about their medical care in the event that they become incapacitated 
or cognitively impaired during the course of the study. Note: The PI  [INVESTIGATOR_148364] (ACAT)  for evaluation as needed for the following: an 
independent assessment of whether an individual has the capacity to provide consent; assistance in identifying and assessing an appropriate surrogate when indicated; and/or an assessment of the capacity to appoint a surrogate.  For those subjects that become incapacitated and do not have pre-determined substitute decision maker, the procedures described in NIH HRPP SOP 14E for 
appointing a surrogate decision maker for adult subjects who are (a) decisionally impaired, and (b) who do not have a legal guardian or durable power of attorney, will be followed. 
12.4 E
VALUATION OF BENEFITS AND RISKS/DISCOMFORTS  
12.4.1 Risks  
[IP_ADDRESS]  Study drugs  risks  
[IP_ADDRESS].1 VX-970 (M6620)  
VX-970 (M6620) was generally well tolerated when administered  as either single -agent therapy 
or in combination with 1 or 2 chemotherapeutic agents to subjects with solid tumors. There were 
no dose-limiting toxicities (DLTs), few adverse events (AEs) leading to study drug discontinuation, and [ADDRESS_401578] subjects receiving VX-970 (M6620) as single- agent or combination therapy had AEs.  
Risks due to M6620 alone 
• Nausea 32%  
• Vom iting 12% 
• Infusion site reactions 9% 
• Systemic infusion reactions  17% 
Risks when  M6620 is given with chemotherapy 
• Nausea 54%  
• Vomiting 33% 
• Infusion site reactions 10% 
• Systemic infusion reactions  15% 
Additional  risks of M6620 given in combination with carboplatin  
• Anemia  52% 
• Low neutrophils 45% 
• Low platelets 38% 
In addition, the following very common adverse events were observed in at least 15% of subjects receiving  M6620 monotherapy. There is not enough experience in M6620 whether these trul y are 
side effects.  
• Diarrhea 15% 
• Fatigue 20% 
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/2020  
 
53 
 There is a possibility that M6620 may make patient  more sensitive to sunlight. VX-970 (M6620) 
absorbs in the UV-visible radiation spectrum and is widely distrib uted includ ing skin, so patients 
receiving VX -970 (M6620) should take protective measures to minimize sun exposure.  
[IP_ADDRESS].2 Topotecan  
Likely , some may be serious (experienced by [CONTACT_726] 20% of subjects taking the drug) 
• Anemia which may require a blood transfusion 
• Low white blood cell counts 
• Constipation, diarrhea, nausea, vomiting 
• Fever  
• Pain 
• Bruising, bleeding 
• Infection, especially when white blood cell count is low 
• Tiredness  
• Shortness of breath 
Less l ikely , some may be serious (experienced by [INVESTIGATOR_82473] 3 and up to 20% of subject s taking 
the drug) 
• Sores in mouth which may cause difficulty swallowing 
• Headache  
• Cough 
• Scarring of the lungs 
Rare but Serious (experienced by 3% of fewer of subjects  taking the drug) 
• Allergic reaction which ma y cause rash,  low blood pressure, wheezing, shortness of 
breath, swelling of the face or throat 
• Low white blood cell counts which may result in life -threatening infections 
[IP_ADDRESS]  Biopsy risks  
The risks associated with biopsies are pain and bleeding at the biopsy site. In order to minimize 
pain, local anesthesia wil l be used. Rarely, there is a risk of infection at the sampling s ite. CT 
guidance may be used in obtaining biopsies. 
[IP_ADDRESS]  Radiatio n risks 
There will be a risk  of ex posure to radiation from [ADDRESS_401579] scans.  The 
amount of radiation exposure is 12.3 rem. The risk of getting cancer from the radiation exposure 
in this study is 1.2 out of 100 (1.2%) and of getting a fata l cancer is 0.6 out of 100 (0.6%). 
[IP_ADDRESS]   CT contrast risk s 
Itching, hives or headaches are possible risk s assoc iated with contrast agen ts that may be used 
during CT imaging . Symptoms of a more serious allergic reaction include shortness of breath 
and swelling  of the throat or other parts of the body. Very rarely, the contrast agents used in CT 
can cause kidney problems for certain patients, such as those with impaired kidney function. 
[IP_ADDRESS]  Release of medical records  
In the course of applying for certain types of in surance (e.g., medical insurance, life insurance, or 
disability insuran ce), people are often asked to sign forms that authorize insurance compani es to 
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/[ADDRESS_401580]’s  request to p rovide the insurance company  with their  medical record.  It is 
possible that information contained in the subject’s  medical record, including any diagnosis of 
cancer, might affect the willingness of th e insurance company to sell them  insurance.    
In addit ion, t he genomic data gen erated from samples will be uploaded to a shared database such 
as dbGaP.  Such databases may be u seful beyond the aims of this particular study, especially as 
various diseases turn out to have mechanisms in common.  The value of th ese data can increase 
when they are shared with the broader research community.  While no traditionally identifying 
inform ation will be shared, it is possible that a subject  or a family member may be i dentified.  
[IP_ADDRESS]  Risk of receiving unwanted information  
Anxie ty and stress may arise as a  result of the anticipation that unwanted information regarding 
disease related DNA sequencing  or disease tendencies, or misattributed paternity. Patients will 
be clearly in formed that the data related to DNA sequencing and gene tic analysis is coded, 
investigational and will not be shared with patients, family members or heal th care providers.  
[IP_ADDRESS]  Risk related to the possibility that information may be released  
This includes the risk that data related to genotype, DNA sequencing or risk for disease tendency 
or trait can be released to members of the public, insurers, employers, or law enforcement 
agenci es. Although there are no plans to release results to the patients, family memb ers or health 
care providers, this risk will be included in the informed consent docu ment. 
[IP_ADDRESS]  Risk to family or relatives  
Family members or relatives may or may not want to be awar e of familial tendencies or genetic 
risks of diseas e which may cause anxiety ab out possible future health problems. As previously 
noted, patients will be notif ied of any medically significant and actionable incidental findings. 
Study results will not be shared with patients.  
[IP_ADDRESS]  Risks related to  blood sampling  
Side effects of blood draws include pain and bruising, lightheadedness, and rarely, fainting. 
[IP_ADDRESS]  Risk related to hair collection  
The only risk associate with hair collection is pain.  
12.4.2 Benefits  
The benefits include a possible decrease in the size of the tumor  and the scientific knowledge 
that could be acq uired through this trial. 
12.5 RISKS/BENE FITS ANALYSIS  FOR SUBJECT S ABLE AND UNABLE TO PROVIDE CONSENT  
Small cell cancer  is an aggressive cancer with a poor prognosis. Patients are in continuous need 
of improved therapy options. This is especially true for patients who have progressed on standard 
therapy such as the patient population that will be eligible for this trial. Phase I clinical data (see 
section 1.2) suggest that Topotecan plus VX -970 (M6620) may improve outcomes in patients 
with small cell c ancers , particularly in thos e with platinum resistant or refractory disease . A 
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/[ADDRESS_401581] been built into the 
protocol through the means of inclusion/exclusion criteria, monitoring strategies, and 
management guideline s. Overall, the study presents more than minimal risk due to protocol-
related procedures and i nterventions with the prospect of direct benefit due to the potential for 
protocol treatment to reduce tumor burden.  
12.6 CONSENT PROCESS AND DOCUMENTATION  
The inform ed consent document will be provided to the participant or consent designee(s) (e.g., 
the parent/guardian if participant is a minor, legally authorized representative [LAR] if 
participant is an adult unable to consent) for review prior to consenting.  A de signated study 
investigator will carefully explain the procedures and tests involved in this study, and the associated risks, discomforts and benefits. In order to minimize potential coercion, as much time as is needed to review the document w ill be given,  including an opportunity to discuss it with 
friends, family members and/or other advisors, and to ask questions of any designated study investig ator. A signed informed consent document will be obtained prior to entry onto the study. 
The initial consent proce ss as well as re -consent, when required, may take place in person in a 
private area (e.g., clinic consult room) or remotely (e.g., via telephone or other NIH approved remote platforms) per discretion of the designated study investigator and with the agr eement of 
the participant/consent designee(s).   
13 PHARMACEUTICAL INFORMATION   
13.1 VX-970
 (M6620) 
13.1.1 Source  
VX-970 (M6620) w as initially  manufactu red and provided by [CONTACT_325209].  As of 
July 2018, the drug is manufactured and provided by [CONTACT_28734].  Toxicity  
[IP_ADDRESS]  Pre-clinical toxicity  
VX-970 (M6620) was administered by [CONTACT_325210] 28 days. The or al studies used a freq uent dosing regimen (every other day) to define the toxicity profile, 
while the IV d osing regimen in the GLP 28-day studies (biw) were more representative of the 
planned clinical dosing schedule (intravenously, once per week). T he rat  STD10 was determined 
to be 30 mg/kg/day and the dog HNSTD was determined to be 20 mg/kg/day, both adminis tered 
via [ADDRESS_401582], ALT, bilirubin and alkaline phosphatase; change s in red cell mass in th e periphery without corresponding bone 
marrow pathology; and testicular atrophy. Major toxicities in the rat also included alterations in red cel l mas s, without microscopic correlates in the bone marrow and testicular atrophy, as we ll 
as phlebitis. No corr esponding change in testes weights were observed in dogs, although 
microscopic findings of degeneration/atrophy were identified. Importantly, degeneration/atrophy in the te stes was reduced during the recovery period in both rats and dogs, providing evidenc e 
that these changes are reversible.  
[IP_ADDRESS]  Clinical Toxicity 
VX-970 (M6620) was being evaluated by [CONTACT_325211]12-970-001 (Study 001). This is a 
first-in-human (FIH) study, evaluating the safety, tolerability, and PK of VX -970 (M6620) as a 
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/2020  
 
56 
 single agent and in combination with gemcitabine, cisplatin and gemcitabine, cisplatin, and 
cisplatin and etoposide. Preliminary safety data fr om Study 001 (data cut -off date: 19 June 2013) 
are available for [ADDRESS_401583] 1 adverse event (AE) which was considered related or possibly related to the study drug ( VX-970 ( M6620) or gemcitabine) by [CONTACT_093]. The 
most common related or possibly drug- related AEs by [CONTACT_325212], followed by [CONTACT_325213], nervous system disorders, and skin and subcutaneous tissue disorders. The most common drug-related or po ssibly drug- related AEs by [CONTACT_325214] (5 subjects), vomiting (4 
subjects), fatigue (3 subjects), and rash (3 subjects). 
In addition to the detailed data  on AEs through 19 June 2013, data on SAEs are available through 
18 September 2014. A total of 30 SAEs occurred in  16 subjects in Study 001 and a second study, 
Study 002, which is testing the safety, tolerability, and pharmacokinetic/pharm acodynamic 
profil e of VX-970 (M6620) as a sin gle agent and in combination with carboplatin in subjects 
with advanced solid tumors. T hree of these SAEs, all of which were unrelated to  study drug, 
were fatal. The most common SAEs (>[ADDRESS_401584]) were pyrexia (4  subjects) and dis ease 
progression (2 subjects). A total of [ADDRESS_401585] receiving 140 mg/m2 VX-970 (M6620), has been identified as an adverse drug r eacti on (ADR) for VX -970 
(M6620). 
Target organs for VX -970 (M6620) toxicity were considered the liver, testes, an d peripheral 
blood cell populations. Importantly, liver and peripheral blood toxicities were reversed within 4 weeks of disco ntinuation of VX-970 (M6620), and both toxicities are readily monitored by 
[CONTACT_325215]-in-human study. Testicular 
degeneration is not an infrequent complication of cytotoxic chemotherapy, and sperm counts ar e 
not routinely followe d in subject s receivin g chemotherapy. Importantly, testicular findings 
showed evidence of reversibility in  both rats and dogs. Finally, subjects will be required to use 
contraception while on study drug and for 6 months afterwards [ 6
].  
13.1.2 VX-970 (M6620) (NSC 780162) Othe r Names  
VRT-0768079, VE-822 
13.1.3 Classification  
ATR inhibitor 
13.1.4 Molecular Formula: C24H26ClN5O3S M.W.: 500.01 Da  
13.1.5 Mode of Action  
Ataxia telangiectasia mutat ed and Rad3- related (AT R) kinase is an api[INVESTIGATOR_325183]. The DNA damage response (DDR) is regulated by [CONTACT_325216] (ATM) kinase, which are recruited to distinct DNA damage structures. VX -970 (M6620) disrupts ATR- mediated DNA damage response signaling 
and leads to sustained accumul ation of DNA damage in cancer cells co -treated with DNA -
damaging agents.  
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/2020  
 
57 
 13.1.6 Description  
The drug substance for VX -970 (M6620) is the HCl salt.  
13.1.7 How Supplied  
VX-970 (M6620) is  supplied by  [CONTACT_325217] -use 200 mg vials containing a sterile 
solution (20 mg/mL). VX-970 (M6620) solution for injection is a yellow liquid formulated in 
20% betadex sulfobutyl ether sodium (w/v) and [ADDRESS_401586] boxes with foam inserts.  
13.1.8 Preparatio n  
VX-970 (M6620) solution for injection must be diluted with 5% dextrose in water solution prior to administration. Do not use 0.9% Sodium Chloride due to incompatibility with VX-970 (M6620). To pr epare the infusion solution add the dose volume of VX-970 (M6620) to a non-
polyvinyl chloride (non- PVC), di(2 -ethylhexyl) phthalate (DEHP)-free EVA infusion bag 
containing 5% dextrose in water. Gently invert the IV bag 5 -10 times to mix the solution . 
Confi rm the  solution is clear and free of precipi[INVESTIGATOR_25466]/or particulates. The final concentration 
must be between 0.075 mg/mL to 1 mg/mL. Place the IV bag into an opaque cover to protec t 
from light.  
Details of dose prep aration for VX- 970 (M6620)  are pr ovided in  (Dose Preparation of VX-970 
(M6620) IV Solution). 
13.1.[ADDRESS_401587] boxes at room temperature, 25°C (77°F), with excursions allowed between 15° and 30°C (59° and 86°F).  
If a storage temperature excursion is identi fied, promptly return VX-970 (M6620) to between 
15° and 30°C and quarantine the supplies. Provide a detailed report of t he excursion (including 
documentation of temperature monitoring and duration of the e xcursi on) to 
[EMAIL_1230]
 for determination of suitabi lity.  
13.1.[ADDRESS_401588] be protected from light 
and used within  4 hours from time of preparation if stored at room temperature or 24 hours if 
stored re frigerated (2° -8°C).  
13.1.11 Route of Administration  
Intravenous (IV) infusion 13.1.12 Method of  Administratio n  
Prior to  administration the solution should be given one hour at ambi ent temperature to warm up 
if stored refrigerated following preparation. Infuse over 60 minutes using an infusion set 
contai ning low-sorption or non- PVC, DEHP -free tubing and an in- line 0.2 m icron filter. 5% 
dextrose in water solution must be used f or IV l ine priming and flushing. VX-970 (M6620) 
should not come in contact [CONTACT_4490] 0.9% Sodium Chloride due to incompatibility. The infusion time may be extended beyond 60 minutes (as tolerated) but no mor e than [ADDRESS_401589] 
procedures to limit symp toms of an infusion reaction are insufficient or if the total volume of the 
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/2020  
 
58 
 infusion exceeds 600 mL. To minimize the possibility of  phlebitis, VX-970 (M6620) should be 
administered through a large bore cat heter i nto a large caliber peripheral vein or central veno us 
access.  
13.1.13 Patient Care Implications  
Monitor for infusion site reactions, irritation, and phlebitis. VX-970 (M6620) absorbs in the UV-
visible radiation spec trum and is widely distrib uted includ ing skin, so patients receiving VX-970 
(M6620) should take pr otective measures to minimize sun exposure.  
13.1.14 Potential Drug Interactions  
VX-970 (M6620) is primarily metabolized by [CONTACT_097]3A4. VX-970 (M6620) has a low potentia l to 
inhibit CYP1A2, 2C9, 2C19, 2D6, an d 3A4, and a moderate potential to reversibly inhibi t 
CYP2E 1. The potential for VX-970 (M6620) to induce CYP450 enzymes is low. Concomitant 
adminis tration with strong inhibitors or inducers of CYP3A4 should be avoided. 
13.1.[ADDRESS_401590] that VX-970 (M6620) is a sub strate of CYP3A and its 
systemic exposure may be affected by [CONTACT_325218] s trong CYP3A inhibitors 
and inducers. Prior and concomitant medication and food restri ctions are provided in Table 4. 
Based upon in vitro data, VX-970 (M6620) is not a potent inhibitor or inducer of human CYP 
enzymes in isolated enzyme systems, theref ore the probability of VX-970 (M6620) interaction 
with other medication s that ar e substrates of CYP metabolism is expected to  be low.  
13.2 TOPOTECAN  
For pharmaceutical information , see the Topotecan Package Insert.  
13.2.1 Administration Procedures 
Please refer to se ction 3.1.2. 
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/2020  
 
59 
 14 REFERENCES  
1. van Meerbeeck, J.P., D.A. Fennell, and D.K. De Ruysscher, Small-cell lung cancer. 
Lancet, 2011. 378(9804): p. 1741-55. 
2. Di M icco, R., et al., Interplay between oncogene-induced DNA damage response and 
heterochromatin in senescence and cancer. Nat Cell Biol, 2011. 13(3): p. 292-302. 
3. Peifer , M., et al., Integrative genome analyses identify key somatic driver mutations of 
small -cell lung cancer.  Nat Genet, 2012. 44(10): p. 1104-10. 
4. Al-Ahmadie,  H., et al., Synthetic let hality in A TM-defici ent RAD50 -mutant tumors 
underlies outlier response t o cancer therapy.  Cancer Discov, 2014. 4 (9): p. 1014-21. 
5. Fokas, E., et al., Targeting ATR in vivo using the novel inhibit or VE-822 results in 
selective sen sitization of pancreatic tumors to radiation. Cell Death Dis, 2012. 3: p. e441. 
6. Vertex, Investi gator's Brochure: VX-970. 2014. 
7. Hall, A.B., et al., Potentiation of tumor responses to DNA damaging therapy by [CONTACT_325219] -970. Oncotarget, 2014. 5(14): p. 5674-85. 
8. J osse, R., et al., The ATR inhibitors VE-821 and VX-970 sensitize cancer cells to 
topoisomerase I inhibitors by [CONTACT_325220].  Cancer Res , 2014. 
9. Ramlau, R., et al., Pha se III study comparing oral topot ecan  to intra venous docetaxel in 
patients with pretreated advanced non- small -cell lung cancer.  J Clin Oncol, 2006. 
24(18): p. 2800-7. 
10. Eisenhauer, E.A., et al., New response evaluation criteria in solid tumours: revised 
RECIST guideline (version 1.1). E ur J Cancer, 2009. 45(2): p. 228-47. 
11. Rustin, G.J.S., et al., Re: New guidelines to evaluate the response to treatment in solid 
tumors (ovarian cancer ). Journal of the National Cancer Institute, 2004. 96 (6): p. 487-
488. 
12. Bubley, G.J., et al., Eligibility  and resp onse guidelines for phase II clinical trials in 
androgen-independent prostate cancer: Recommendations from the prostate- specific 
antigen working group. Journal of Clinical Oncology, 1999. 17(11): p. 3461-3467. 
13. Scher, H.I., et al., D esign a nd end points of clinical trials for patients with progres sive 
prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J C lin Oncol, 2008. 26(7): p. 1148-59. 
14. Vergote, I., et al., Re: Ne w guid elines to evaluate the response to treatment in solid 
tumors [ovarian cancer].  Journal of the National Cancer Institute, 2000. 92 (18): p. 1534-
1535. 
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/2020  
 
60 
 15 APPENDICES  
15.1 APPENDIX A- PERFORMANCE  STATUS  CRITERIA 
ECOG Performance Stat us Scale 
 Karnofsky Performance Scale  
Grade  Descripti ons Percent  Description  
0 Normal activity.  Fully active, 
able to carry on all pre- disease 
performance without restriction.  100 Normal, no complaints, no 
evidence of disease.  
90 Able to carry on nor mal activ ity; 
minor signs or symptoms of disease.  
1 Symptoms, but ambulatory.  Restricted in physically strenuous activity, but ambulatory and able to carry out work of a light or sedentary nature (e.g., light housewor k, office work).  80 Normal  activi ty with effort ; 
some signs or symptoms of disease.  
70 Cares fo r self, unable to carry on 
normal activity or to do active work. 
2 In bed <50% of the t ime.  
Ambulatory and capable of all self-care, but unable to carry out 
any work activities.  Up and about more than 50% of waking 
hours. [ADDRESS_401591] of his/her needs. 
50 Requires considerable assistance and frequent medical care.  
3 In bed >50% of the time.  
Capable of o nly limited self -care, 
confined to bed or chai r more 
than 50% of waking hours. 40 Disabled,  requir es special care 
and assistance.  
30 Severely disabled, hospi[INVESTIGATOR_374].  Death not imminent.  
4 100% bedridden.  Completely disabled.  Cannot carry on any self-care.  Total ly conf ined to bed 
or chair.  20 Very sick, hospi[INVESTIGATOR_374]. De ath not imminent.  
10 Moribund, fatal processes progressing rapi[INVESTIGATOR_375]. 
5 Dead.  0 Dead.  
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/2020  
 
61 
  
15.2 APPENDIX B- STRONG  INHIBITORS  AND  INDUCERS  OF CYP3A 
Strong Inhibitors  Strong Induc ers 
boceprevir  
clarithromycin  
conivaptan 
grapefruit juice (1)  
indinavir itraconazole  ketoconazole lopi[INVESTIGATOR_054]/ritonavir  
mibefradil (2) nefazodone  nelfinavir posaconazole ritonavir 
saquinavir telaprevir  
telith romycin 
voriconazole 
 avasimibe (4) 
carbamazep ine 
phenytoin rifampin  
St. John’s wort (3)
 
 
http://www.fda.gov/Drugs /DevelopmentApprovalProcess/Devel opme ntResourc es/DrugInteractionsLabeling/ucm093664.htm#cla
ssInhib it 
1. The effect of grapefruit juice varies widely among brands and is concentration- , dos e-, and preparation-
dependent. Studi es have shown that it can be class ified as a “strong CYP3A i nhibito r” when a cer tain 
preparation was used (e.g., high dose, double strength) or as a “moderate CYP3A inhibitor” when another 
preparation was used (e.g., low  dose, single strength).  
2. Withdrawn f rom the [LOCATION_002] market because of safety reasons. 
3. The effect of St. John’s  wort varies widely and is preparation -depend ent. 
4. Not a marketed drug.  
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/2020  
 
62 
  
 
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/2020  
 
63 
   
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/2020  
 
64 
   
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/2020  
 
65 
   
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/2020  
 
66 
   
Abbreviate d Title:  Topotecan + M6620 in Sm Cell  
Version  Date:  06/12/2020  
 
67 
   